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ABSTRACT 
The only curative treatment strategy for many hematologic and inborn immunodeficiency 
disorders is an allogeneic hematopoietic stem cell transplantation (HSCT). The treatment 
involves replacing the entire hematopoietic system of the recipient. If successful, the 
underlying condition of the patient is resolved, the donor hematopoietic system engrafts and 
a tolerance between donor- and patient-derived cells is developed. Though the procedure of 
HSCT has been refined for decades, there are still several severe complications associated 
to it. 
 
Graft-versus-host disease (GVHD) is one of the most common and most feared 
complications post-HSCT, and is a result of donor graft-derived cells attacking recipient 
tissue. Despite improved GVHD treatment strategies, severe grade GVHD is still associated 
with high morbidity and mortality rates. A condition known as mixed chimerism (MC), 
where recipient hematopoietic cells co-exist with donor hematopoietic cells, may also be 
considered an adverse event early post-HSCT. This is certainly the case for patients with 
malignancies as it indicates a potential relapse. However, in rare cases where HSCT is 
performed due to non-malignant disorders, long-term stable MC may develop without any 
apparent signs of unfavourable symptoms.  
 
The papers in this thesis aim to provide a better understanding of the co-existence of graft- 
and host-derived cells from an immunological perspective. I will focus on GVHD and long-
term stable MC post-HSCT particularly. 
 
In Paper I, I aimed to identify predictive markers for acute GVHD development. Acute 
GVHD occurs relatively shortly post-HSCT with potential devastating effects. In this paper, 
I observed a reduced frequency in mucosal-associated-invariant T (MAIT) cells in donor 
grafts, given to patients who later developed acute GVHD. Moreover, I could identify a 
predictive role for high PD-1 and low CD127-expressing T cell frequencies in the donor 
grafts. Together with increased levels of TNFa in both the donor graft and in patient 
plasma prior to HSCT, these findings may putatively be used to predict acute GVHD 
development in patients at time of transplantation.  
 
In Paper II, I focused on chronic GVHD, a complication that usually develops later post-
HSCT presenting with symptoms from several organs. Patients may suffer from chronic 
GVHD for years, resulting in a diminished quality of life. In this paper, I was able to 
identify novel cellular subsets via mass cytometry that could be linked to the severity of 
chronic GVHD. These subsets could also be identified by conventional flow cytometry 
panels more suitable for routine laboratories. Additionally, similar to the study on acute 
GVHD, patients with more pronounced chronic GVHD were found to have fewer MAIT 
cells in their blood. Thus, Paper I and II indicate a potential role for MAIT cells in both 
acute and chronic GVHD. 
 
In Paper III and IV, the focus was long-term stable MC, which is defined as the presence 
of 5-95% recipient-derived cells, after ≥5 years post-HSCT in this study. Interestingly, 
patients with long-term stable MC had a similar quality of life, infectious disease burden 
and response to vaccines compared to patients with full donor chimerism (DC). 
Fluctuations in recipient chimerism tended to decrease and reach stable levels after around 
two to five years post-HSCT. Moreover, patients with MC appear to retain functional 
recipient-derived cells in multiple cellular subsets. Patients with MC also displayed 
increased levels of IgG3 and reduced lymphocyte expression of ZAP-70, though they were 
found to be similar to patients with DC in overall immune phenotype.  
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1 INTRODUCTION 
 
1.1 THE IMMUNE SYSTEM 
Our bodies are under daily attack by pathogens, organisms that cause harm or disease. 
Pathogens range from viruses, bacteria to parasites. To combat them, an intricate defence 
system called the immune system is active round-the-clock. The immune system consists of 
an extensive network of cells present in (almost) all parts of our body, and has the ability to 
communicate and develop appropriate defence strategies specific to the type of invading 
pathogen. The importance of this intricate system becomes evident when we consider 
patients with immune deficiency disorders, who may suffer from lethal infections. 
Additionally, from an evolutionary standpoint, the immune system has proven to be an 
essential part of life. We can observe similar systems in other animals and even in plants, 
albeit in a more rudimentary form in the case of the latter.1, 2 This indicates the necessity 
and importance of immune systems and that they have co-evolved with us and the 
pathogens trying to invade.  
 
The immune system can be divided into two general “arms”; the innate and the adaptive. 
The innate arm is considered more evolutionary conserved. Versions similar to the innate 
system have been observed in most animals, both in invertebrates and vertebrates. 
Variations of the adaptive system, on the other hand, are only seen in vertebrates. 
Particularly so in the jawed-vertebrates, which includes fish, amphibians, reptiles, birds and 
mammals.2, 3  
 
Innate immunity is considered to be our first line of defence. As such, its responsibilities 
are to; first of all, keep pathogens out; secondly, to kill pathogens that do manage to get 
through; and finally, to raise the alarm if the pathogens cannot be quickly destroyed. In 
order to do this, it needs to be able to respond fast. Hence, the innate system acts within 
seconds to hours after an infection. It is, however, restricted in its ability to learn. Adaptive 
immunity takes several days to weeks to be activated, but it can adapt its response to the 
pathogen and can learn from previous encounters and thus improve.  
 
A large variety of immune cells form our immune system. All immune cells derive from a 
common progenitor, the hematopoietic stem cell (Figure 1). The different immune cell 
types will be discussed in some detail in the relevant sections. The development of a stem 
cell to an immune cell can be categorized in two distinct lineages, lymphoid and myeloid. 
The myeloid lineage ultimately forms the innate arm, while the lymphoid lineage primarily 
forms the adaptive arm, though not exclusively. This process of formation of all blood cells 
(including erythrocytes, thrombocytes and all immune cells) is called haematopoiesis. It is 
continuously occurring throughout human life, and is essential to a healthy immune system 
function and its continuous renewal. 
 
This introduction will only touch upon some of the basics of the immune system. For a more 
comprehensive discussion of the immune system I would like to refer to two excellent textbooks on 
this matter; Parham’s “The Immune System” and Janeway’s “Immunobiology”.4, 5  
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1.1.1 Innate Immunity 
Innate immunity is fast-acting. Some of its components react within seconds to a pathogen 
and others may take minutes to hours. It can react so quickly as its parts are continuously 
patrolling and/or present. For instance, physical barriers, like the skin and mucosa, deter 
pathogens from entering our bodies. These barriers are considered to be an important part 
of innate immunity. Another example is macrophages, which continuously patrol directly 
below our skin, and may react within minutes to a pathogen. To understand how the innate 
immune system operates, it is perhaps easiest to illustrate by following a daring pathogen 
on its quest to invade an unsuspecting human. We will thus see how the innate immune 
system deals with the pathogen.  
As mentioned, the first barrier a pathogen will need to overcome is the skin or the mucosa. 
The skin is protected by several layers of epithelial cells, a colony of commensal bacteria 
and fungi and antimicrobial peptides. Similarly, mucosal layers consist of layers of mucus 
and/or colonies of bacteria limiting the ability of the pathogen to attach and proliferate.6 
Therefore, in order to get past these barriers, a pathogen will need to exploit a physical 
disruption. This can vary from a cut, a reduced layer of mucus or a lack of commensal 
bacteria (for instance after an intensive antibiotic treatment). For our story’s purpose, we 
will assume our pathogen has managed to gain entrance via a cut on a finger.  
 
The presence of the cut is detected by the body, as damaged cells in the area send out 
warning signals; chemokines, cytokines and other soluble factors.4, 5, 7 Cytokines and 
chemokines are small soluble proteins or protein-fragments essential for cellular 
communication, both short and long distance. They can affect the actions of cells around 
them and, as such, play a vital role in both the innate and adaptive immunity. Additionally, 
the pathogen itself might excrete toxins, which can also act as warning signals.4, 5 Resident 
macrophages that patrol the deeper layers of the skin are attracted by the signals and will 
move towards the injury. There they will come into contact with the pathogen and the 
damaged and dead cells. They will clean up the site, a process known as phagocytosis 
(Figure 2) to remove the pathogen and destroyed tissue.8, 9 Epithelial cells of blood vessels 
Hematopoietic	
stem	cell
Myeloblast
Common	myeloid
progenitor
Common	lymphoid
progenitor
Megakaryoblast
Megakaryocyte
Thrombocytes
Proerythroblast
Polychromatic	
erythroblast
Erythrocyte Mast	cell
Lymphoid	
dendritic	 cell
Myeloid	
dendritic	 cell Plasma	cellMacrophage
Natural	 killer	cellB lymphocyte T lymphocyte
Lymphoblast
Basophil Neutrophil EosinophilMonocyte
Meyeloid lineage Lymphoid lineage
Figure 1. Schematic of haematopoiesis in humans, the development from a hematopoietic stem cell to the most common 
blood cells. 
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in the area also react to the warning signals and become more porous leading to an influx of 
fluid into the affected area. The fluid carries platelets or thrombocytes to the site of injury 
which will clot the cut and prevent more pathogens from entering the body. Additionally, 
immune cells from the blood that are attracted by the chemokines and cytokines will 
migrate towards the injury. An example of such immune cells that arrive from the blood to 
the site of infection, are neutrophil granulocytes or neutrophils. Neutrophils are able to 
engulf and destroy large quantities of free roaming pathogens, which they will continue to 
do until they die. The dead neutrophils combined with dead pathogens form pus, which can 
ooze from a particularly nasty wound.4, 5 
This bodily response to the cut and the pathogen is called an inflammatory response. It is 
characterized by local pain, redness of skin, swelling and warmth of the tissue around the 
injury. To clarify, an infection describes the invasion of the pathogen into the human body, 
while inflammation is the response of the body towards the infection. 
 
In most cases, the inflammatory response is sufficient to kill the pathogen and all is well 
once more. However, in some cases the response is unable to eliminate the pathogen at this 
early stage of infection. Another innate immune cell, the dendritic cell, will then start to 
play a vital role. This cell is continuously present in tissues and will phagocytose the 
pathogen. Unlike a macrophage and neutrophil, a dendritic cell’s prime function is not to 
just phagocytose as many pathogens as possible. It will instead engulf only some 
pathogens, kill those, process them and then start displaying parts of the pathogen on its 
surface. This is called “presenting antigen” and is required to involve certain other immune 
cells. While the dendritic cell does this, it moves away from the site of injury towards the 
closest draining lymph node, which serves as a meeting point with other immune cells.4, 5 
 
Lymph nodes are part of an intricate lymphatic system. In the skin, the lymphatic system 
works as follows. Fluid is constantly pushed out from capillaries into tissue at low volumes 
to supply tissue with nutrients and oxygen. Most of the fluid is reabsorbed by the blood 
vessels through osmotic pressure, but not all. The remaining fluid is sort of trapped and 
needs to be transported away, lest we would all swell up like balloons after a while. The 
fluid, now called lymph, flows into small vessels, called lymphatics. The lymphatics drain 
the lymph towards draining lymph nodes. In these lymph nodes, immune cells are present 
that “taste” the lymph for the presence of pathogens. Ultimately, the lymph will leave the 
lymph node via another draining lymphatic and flow towards the next lymph node. The 
lymph will pass several lymph nodes to ultimately drain into a major vein and thus back 
into the blood circulation, completing the circle.4, 5 
 
Figure 2. A representation of phagocytosis. Bacteria are engulfed by the cell into a phagosome. The phagosome fuses 
together with a lysosome, which contains a variety of enzymes. The enzymes destroy the bacteria into smaller proteins, 
which may be easily disposed of or loaded onto receptors to display on the surface of the cell. 
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Lymph nodes are not the only lymphoid organs in the human body. A distinction can be 
made between central or primary and peripheral or secondary lymphoid organs. In the 
central lymphoid organs, (adaptive) immune cells are produced, while in the peripheral 
lymphoid organs, (adaptive) immune cells start their activation process. Examples of 
central lymphoid organs are the thymus and bone marrow (BM). Examples of peripheral 
lymphoid organs/tissue are the lymph nodes, the tonsil, the spleen and Peyer’s patches in 
the gut.4, 5  
 
For our example of the pathogen, the dendritic cell is transported together with the lymph to 
a nearby draining lymph node. In the lymph node, the dendritic cell can interact with cells 
from the adaptive immune system via the displayed antigen. If an antigen is recognized, 
communication between the two arms is initiated (innate and adaptive). The adaptive 
immune system can now be activated and help destroy remaining pathogens that the innate 
immune system was unable to eliminate.  
 
Before I move towards explaining adaptive immunity, there is one more aspect of the innate 
system that needs to be mentioned. Some pathogens have devised a method to avoid 
detection and being killing by the innate immune system. In the example so far, we have 
assumed that the pathogen stays outside of human cells, e.g. extracellular. However, viruses 
and some bacteria will invade a cell, hence they are called intracellular pathogens. This 
subterfuge will help hide them from the parts of the immune system that have been 
mentioned before.  
 
Luckily, dendritic cells are not alone in their ability to present antigens at their surface. 
Almost all cells in the human body continuously present antigens. If there is no pathogen, 
antigens are presented from degraded proteins from within the cell, this is called presenting 
self-antigen. Thus, under normal conditions, cells only present self-antigens. However, if a 
cell is taken over by a virus or an intracellular bacterium, antigens from the pathogen will 
be presented on the surface. An infected cell is then visible and can be detected by the 
immune system.4, 5 
 
To avoid this, some intracellular pathogens have evolved and developed an additional 
escape mechanism. Once these pathogens enter the cell, they prevent the infected cell from 
displaying pathogen-derived antigens on the surface by preventing the production of certain 
receptors.10 Natural selection however, came up with a smart response to counteract this 
escape mechanism. A natural killer (NK) cell attacks and kills cells that lack (or display 
very low amounts of) the antigen presenting receptors on the surface. This is called the 
“missing-self hypothesis”.11, 12 An NK cell regulates its response with a combination of 
inhibitory and activating receptors.13, 14 To conclude, the pathogen now faces a dilemma: 
downregulate the antigen presenting receptors of the infected cell and risk being killed by 
NK cells, or leave the receptors alone and risk being killed by cells from the adaptive 
immune system.  
 
The system of antigen presenting receptors is called the human leukocyte antigen (HLA) 
system, or the major histocompatibility complex (MHC). The latter is the more universal 
way of addressing this system as it can be used for all animals, while the HLA system is 
specific for humans. In short, the HLA system is the collection of molecules that cells use 
to present antigen to the rest of the body. The antigens that can be displayed consist of 
small peptides which have been cleaved from larger proteins inside the cell. These large 
proteins can, as mentioned, vary from self-proteins, viral proteins or phagocytosed 
pathogen proteins.4, 5 
 
  5 
There are two HLA classes. HLA class I binds and presents antigen that was produced 
within a cell, therefore, presenting the status of the inside of a cell. Almost all cells have 
HLA class I molecules on their surface. HLA class II binds antigen that was sampled from 
outside of the cell, demonstrating how the environment of the particular cell looks like. 
Only a certain number of specialized cells, called antigen presenting cells (APCs), have 
HLA class II molecules on their surface, dendritic cells being one of the important ones.4, 5  
 
There are thousands of different HLA alleles (>9.000 class I and >2.500 class II alleles) 
currently known.15 Each allele codes for a specific HLA receptor. The binding sites of the 
HLA receptor determine the peptide it can bind and thus present to its environment. 
Different HLA receptors can bind and present different peptides from the same pathogen. 
Each individual has only a select number of HLA alleles, as such a large variety of 
combinations of alleles is possible across the human species. Some HLA alleles are 
however more common within certain populations than other HLA alleles. Since some 
HLA receptors are better at binding antigens from certain pathogens, these receptors are 
more prevalent in areas where these pathogens are endemic.16 An evolutionary selection of 
HLA alleles based on endemic pathogens in a region can be observed. Therefore, while the 
chance of two unrelated individuals having the exact same set of HLA alleles is small, it is 
not impossible. For siblings, the chance of having the same HLA alleles is much higher; 1 
in 4, as we receive half of our HLA haplotypes from each parent.4, 5  
 
At this point I feel that I must point out that there are several more aspects of the innate 
immunity that are important for its function that I have not mentioned yet. For instance, the 
innate system actually relies quite heavily on pattern recognition receptors such as Toll-like 
receptors and NOD-like receptors to identify pathogens. Another example is the 
complement system, which is also a part of the innate immune system. The complement 
system functions as a cascade of small soluble proteins which ultimately can kill pathogens 
by punching holes in their membranes or by making pathogens appear more recognizable as 
such for other immune cells.4, 5 I will not discuss these aspects of the innate immunity in 
detail as they fall outside the scope of this thesis. 
 
In short, the innate system plays a vital role in our survival. Individuals without an innate 
immune system or a severely dysfunctional innate system do not survive for long. The main 
reason for this is that the innate system is continuously patrolling and can act within 
minutes, while the adaptive immune system is slow in response and needs several days to 
mount an effective response. The major disadvantage of the innate immune system is its 
inability to adapt and change its response to better fit the pathogen in question. The 
adaptive immune system adapts (hence the name) its response to the pathogen and becomes 
more specific and effective as time goes on. 
 
 
1.1.2 Adaptive Immunity 
As mentioned before, during an infection, dendritic cells from the innate immune system 
will phagocytose and process pathogens. They then migrate to the closest lymph node and 
start to present pathogen derived antigens on their HLA molecules. In the lymph node, the 
dendritic cell will encounter T and B lymphocytes, which are present in separate areas of 
the lymph node. These two cell types, and their many subtypes, form the adaptive immune 
system.4, 5  
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1.1.2.1 T Lymphocytes 
T lymphocytes, or T cells, all have the T cell receptor complex (TCR) on their surface. 
With these TCRs they can interact with the HLA receptors on other cells. Each T cell 
displays multiple copies of the same TCR on its cell surface. Each TCR can recognize only 
one specific antigen, hence, each T cell is specific for only a single antigen. We have 
several millions of different specific T cells in our bodies. Only a few will ever encounter 
their specific antigen, the vast majority will never encounter “their” antigen in their 
lifetime.4, 5  
 
The TCR (Figure 3) consists of a collection of protein chains with both extracellular and 
intracellular domains. The binding chains of the TCR are extracellular and are anchored 
into the cell membrane. They consist of an a and b chain which together interact with the 
antigen presented by the HLA receptor. Most specifically, the outmost part of the 
extracellular domains interacts with the HLA receptor as this is the variable region. The 
lower part forms the constant region and anchors the chains into the cell membrane.4, 5  
The TCR complex also contains the cluster of differentiation (CD)3 complex. The CD3 
chains are the signalling domains that start a cascade of activation internally if a TCR binds 
to an HLA receptor and recognizes the antigen presented by it. CD3 is expressed on all T 
cells at a high number and is therefore a good marker for analysis.  
 
Each T cell has a unique a and b chain and can thus recognize unique antigens. However, 
the TCR first needs to recognize and bind to the HLA receptor. For this it uses two co-
receptors (CD4 or CD8) associated to the TCR. A mature T cell, generally, can only 
express CD4 or CD8, not both, and are classified to be either CD4+ or CD8+. CD4+ and 
CD8+ T cells have very distinct functions which will be discussed in more detail later on. 
! " # !
$$
! " # !
$$
% β % β
CD4
CD8
TCR TCR
CD3 CD3CD3CD3
Figure 3. Schematic of the TCR complex. In the left panel, a CD4+ T cell is depicted and on the right a CD8+ T cell. 
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One of the differences is the fact that CD4+ and CD8+ T cells bind different classes of 
HLA molecules. CD4+ T cells recognize HLA class II and CD8+ T cells recognize HLA 
class I molecules.4, 5  
 
T cells have to undergo a maturation and education process to ensure a huge variety in 
TCRs. This development is a complicated and lengthy process. In short, T cells start their 
development in the BM, together with B and NK cells. The T cell progenitors migrate 
towards the thymus where they rearrange their TCR genes and become formally educated. 
During this process, unwanted T cells, for example autoreactive T cells, are removed from 
the T cell repertoire. After this, the cells are primed for function. The T cells migrate from 
the thymus towards the peripheral lymphoid organs, such as the lymph nodes, in search of 
their antigen. Upon encountering their antigen, the T cells are activated, proliferate and 
migrate towards the site of infection where they will engage the pathogen. Each of these 
phases in T cell development will be discussed in some detail below. 
 
T cells are formed from a common NK/T/B cell precursor in the BM, called the common 
lymphoid progenitor (CLP). Some of these progenitors leave the BM and migrate towards 
the thymus. These progenitors do not yet express CD3, as they have not yet formed a TCR. 
They also do not yet express CD4 or CD8, and are often called double-negative 
thymocytes. Upon arriving in the thymus, the double negative thymocytes differentiate and 
rearrange their TCR genes. During this rearrangement, or somatic recombination, 
ultimately the TCR complex is formed. The cells start by simultaneously rearranging the 
g,d and b TCR genes. During this rearrangement random segments of V, D and J gene 
segments for the d and b chains, and V and J gene segments for the g chain of the TCR are 
combined. This ensures that a large variety of potential TCRs are created. If a TCRgd is 
formed first, the T cell will become a gd T cell, leave the thymus and move into the 
periphery. However, the vast majority of cells will first form a stable pre-TCR with only the 
b chain, thus committing the T cell to become an ab T cell. As most T cells will become 
ab T cells, I will continue explaining their development. The thymocytes with a stable pre-
TCR will now undergo extensive proliferation to ensure that many thymocytes with the 
same pre-TCR exist. At the end of this proliferation, the cells will also start to display both 
CD4 and CD8 on the surface in conjunction with the pre-TCR. The thymocytes are now 
referred to as double-positive thymocytes. The a TCR gene is then rearranged and this 
continues until a stable TCRab is formed to replace the pre-TCR containing only the b 
chain. Since the a chain rearrangement is random and since there were many thymocytes 
with the same pre-TCR after the proliferation, an enormous variety of ab T cells are 
created. The thymocytes are now ready to be educated.4, 5, 17, 18 
 
The thymus does not only contain thymocytes, it is also populated with stromal cells that 
display almost any imaginable self-antigen on their HLA (class I and II) molecules. These 
stromal cells are essential for T cell education. The thymocytes are educated via a process 
called positive and negative selection. During positive selection, the thymocytes will move 
around the stromal cells and try to bind to the HLA molecules via CD4 or CD8. The 
thymocytes that can recognize the HLA molecules will bind and receive a survival signal. 
Those that are unable to bind HLA will not receive a survival signal and instead go into 
programmed cell death, a process known as apoptosis. During this selection only T cells 
that can recognize the body’s HLA molecules remain. This is crucial, as T cells need to be 
able to recognize the HLA molecules in the periphery, or they will never be activated. 
During this process, the thymocyte will also commit to be either a CD4+ or CD8+ T cell. If 
the thymocyte binds HLA class I first with the CD8 co-receptor, the T cell will become a 
CD8+ T cell and vice versa for HLA class II and CD4. The unstimulated co-receptor will 
be downregulated.4, 5, 17-19  
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The single positive thymocytes that have survived move onwards to the negative selection 
process. In this phase, they again face the stromal cells displaying self-antigen on HLA 
molecules. This time, they are tested for their potential to recognize and bind self-antigen 
displayed on the HLA molecule. The thymocytes that bind too strongly will receive an 
apoptosis signal as these are potentially self-reactive T cells. Consequentially, those that do 
not bind, or very weakly bind, do not receive an apoptosis signal and will survive. At the 
end of the negative selection we are left with single positive thymocytes that can recognize 
self-HLA but do not recognize self-antigen.4, 5, 19 The thymocytes are now released from the 
thymus and move into circulation. They are now so-called naïve T cells. 
 
Thymal education is an ongoing process throughout life although it is severely diminished 
as we grow older. The thymus starts to degenerate during adolescence and thymic tissue is 
gradually replaced by fat, diminishing thymic function as we age.20 
 
The naïve T cells migrate between the blood and lymph nodes in search of their antigen. 
After encountering and interacting with a dendritic cell presenting their antigen in a lymph 
node, they will become activated. For a naïve T cell to become activated for the first time, 
just recognizing the antigen displayed on HLA is not enough. The naïve T cell will also 
need a co-stimulatory signal, most often in the form of CD28 on the T cell, binding to a co-
stimulatory molecule (e.g. B7) on the dendritic cell.21, 22 Therefore, the dendritic cell needs 
to not only present the pathogen antigen, it also needs to present co-stimulatory signals to 
convince the naïve T cell to activate. This is a protective function, to ensure that naïve T 
cells will not attack tissue unless they receive a strong co-stimulatory signal indicating 
something is wrong. 
 
Binding of the antigen-HLA complex to the TCR and costimulatory complex sets in motion 
an activation cascade. A series of intracellular domains are phosphorylated, recruiting 
proteins like zeta-chain-associated protein kinase 70 (ZAP-70) and lymphocyte-specific 
protein tyrosine kinase (LCK), which continues the downstream signal towards the cell 
nucleus (Figure 4). In short, the TCR binds and recognizes the antigen-HLA complex. The 
co-receptor (CD4 or CD8) then binds to the HLA molecule, leading to a conformational 
change. LCK is recruited to the intracellular part of the co-receptor and is activated. LCK 
phosphorylates certain areas (immune-receptor tyrosine-based activation motifs (ITAMs)) 
on the intracellular parts of the TCR complex. The changes to these areas now allow ZAP-
70 to bind, resulting in its phosphorylation and activation by LCK. The phosphorylated 
ZAP-70 then goes on to phosphorylate other signalling proteins, propagating the signalling 
cascade. In parallel, CD28 binds to another receptor (B7) on the APC, resulting in 
phosphorylation of the intracellular part of CD28. This then results in a cascade of 
recruitment and phosphorylation of several other proteins, phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) being one of the first. Ultimately, transcription factors and 
cytokines are produced resulting in cellular activation.4, 5, 23 For the sake of simplicity this 
introduction will not delve deeper into the mechanisms of TCR activation.  
 
After a naïve T cell has been activated it clonally expands and differentiates from a naïve T 
cell into a central memory and/or an effector memory T cell. The effector memory T cells 
fight the infection, while the central memory T cells function as the immunological 
memory. These central memory T cells can clonally expand quickly should the pathogen 
invade again and will not need a costimulatory signal to do so the second time. This is part 
of the reason why we are usually ill for a longer period the first time we encounter a 
pathogen and a shorter period the second and third time we encounter the same pathogen. 
Additionally, this memory development is the rationale behind vaccinations. By 
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immunizing an individual with a dead or weakened pathogen, the adaptive immune system 
can develop memory against the pathogen. 
 
There are two commonly used models for T cell memory differentiation. In the first model, 
the off-on-off model, naïve T cells differentiate into effector memory T cells. After an 
infection has been removed, most effector memory T cells die but some turn into central 
memory T cells. If an infection reoccurs, the memory T cells can then turn back into 
effector T cells. The second model, the developmental model, states that naïve T cells 
differentiate into central memory T cells first. Some of these central memory T cells will 
then differentiate into effector memory T cells that will fight the infection. The effector 
memory T cells will then go into apoptosis after the infection is cleared. Evidence for both 
models can be found and further research elucidating the exact mechanism is still needed, 
though most evidence does point toward the developmental model. For research purposes, 
expression of the cellular markers chemokine receptor (CCR)7 and CD45RO/CD45RA is 
most often used to classify the differentiated cell types.24 
 
After a sufficient number of effector memory T cells have been formed, the T cells will 
either interact with B cells or leave the lymph node in search for the pathogen. Interaction 
of T and B cells will be explained in more detail later on. The effector T cells that leave the 
lymph node are homed through chemotaxis by chemokines that are released at the site of 
infection. When they encounter the pathogen they no longer need a co-stimulatory signal to 
act.4, 5  
 
T cells come in many, figuratively speaking, shapes and sizes. New subtypes are 
continuously being discovered. We will focus on some of the most abundant subtypes and 
the subtypes most relevant to the contents of this thesis. Conventional T cells can foremost 
be divided into CD4+ and CD8+ T cells. These two T cell subtypes are also termed T 
helper (Th) cells (CD4+) and cytotoxic T cells (CD8+).  
 
B7
CD28
HLA
TCR	complex
CD4+	T	cell
Dendritic	cell
Gene	transcription
Cell	proliferation	&	differentiation
Cytokine	 production
LCK
ZAP-70
PI3K
Figure 4. A representation of the activation of a CD4+ T cell upon encountering its antigen as presented by an HLA 
class II molecule on a dendritic cell. 
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CD4+ T cells are called T helper cells as they mainly facilitate the communication and 
activation of immune cells (Figure 5). Th cells come in varying subtypes; Th1, Th2, Th17, 
follicular helper T cells (Tfh) and regulatory T cells (Tregs) being the most commonly 
described. This classification is mainly based on the cytokines they excrete and the effect 
those cytokines have on other immune cells.  
 
Th1 cells are focused on intracellular pathogens, bacteria and viruses. They mostly produce 
interferon (IFN)g which stimulates macrophages to more effectively phagocytose and 
destroy intracellular pathogens. Th2 cells usually excrete interleukin (IL)-4, IL-5 and IL-13. 
These cytokines influence the function of other types of cells which are mostly associated 
to the defence against extracellular parasites. For instance, activation of mast cells and 
promotion of B cells to isotype switch to IgE. In short, Th1 cells are focused on cytotoxic 
or cellular immunity, while Th2 cells promote humoral immunity, via B cells. Th17 cells 
produce IL-17, which stimulates neutrophils and helps the immune system to fight 
extracellular bacteria and fungi. Tfh cells are important in the communication with B cells. 
These cells form germinal centres with B cells in the lymph nodes where they can influence 
B cell maturation. This process will be described in more detail later on. Lastly, Tregs have 
an immune regulatory function. They dampen the immune response in the periphery to 
ensure that our own immune response does not end up killing us. They are an integral part 
of a critical negative feedback loop.4, 5, 25, 26  
CD4+	T	cell
Cytokines
Activation	of	
macrophages
Activation	of	T	
and	B	
lymphocytes
Dendritic	 cell	
expressing
pathogen	antigen
CD4+	T	cell
CD8+	T	cell
Infected	cell	
expressing
pathogen	antigen
Killing	 of	Infected	cellCD8+	T	cell
Figure 5. Schematic representation of some functions of CD4+ and CD8+ T cells. 
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In contrast to CD4+ T cells, CD8+ T cells do not come in as many subtypes (as far as we 
know). These cells are similar to NK cells, as in they respond to intracellular threats. Upon 
activation, they will migrate around the body in search for cells that have been invaded by 
the pathogen. If they recognize an infected cell, they will destroy it and the pathogen inside 
of it (Figure 5). They kill by releasing perforins and granzymes which punch holes in the 
cell membrane and induce apoptosis after entering the cell, respectively. While CD8+ T 
cells are invaluable in destroying intracellular pathogens, they are potentially also one of 
the most dangerous immune cell subsets to be autoreactive.4, 5  
 
There are also several non-conventional T cells, though these are present at much lower 
frequencies than conventional CD4+ and CD8+ T cells. One of these types of T cells are 
the so-called mucosal-associated-invariant T (MAIT) cells. These MAIT cells are a 
relatively new discovery and can be characterized by their expression of CD161 as well as a 
specific TCR receptor, TCRVa7.2-Ja33.27-30 They are found at low frequencies in the 
blood, around 5% of total lymphocytes, but are present in much higher frequencies in 
mucosal areas of the body, hence their name. These cells do not respond to traditional 
peptides like conventional T cells. Instead, they recognize and are activated by riboflavin 
metabolites, most commonly formed by biosynthetic pathways in bacteria and yeasts. It is 
probably for this reason that MAITs can be found more in mucosal areas, where bacteria 
are more abundant.31, 32 
 
Another subtype of cells are the invariant NKT cells (iNKT). These iNKT cells constitute 
less than 1% of the blood T cells. They have most of the same receptors and markers as NK 
cells, but also have a TCR, making them T cells and not NK cells. Unlike conventional T 
cells, they do not recognize HLA, but are instead CD1d-restricted (an MHC-like molecule). 
Because of this, these cells recognize lipids instead of peptides.31, 33  
 
Lastly, all T cells discussed so far are T cells with a traditional a and b chain TCR. There is 
a subset of T cells that instead have a g and d chain, as briefly alluded to in the section on T 
cell development. These gd T cells do not undergo education in the thymus, but instead 
mature in the periphery. The exact mechanisms of their education are not entirely 
understood yet. Interestingly, gd T cells do not seem to be restricted to HLA for activation, 
such as ab T cells are. While it is not entirely clear how gd T cells are activated, they seem 
to recognize lipids instead of proteins, similar to iNKT cells.31, 34  
 
To conclude, T cells are essential for a successful immune response. They have an 
extremely varied response and recognition repertoire. They are vital, but they are not alone. 
They receive and give a lot of help to B lymphocytes, the other important cell type of the 
adaptive arm. 
 
 
1.1.2.2 B Lymphocytes 
B lymphocytes, or B cells, have a B cell receptor (BCR) on their surface (Figure 6). The 
BCR is essentially a membrane bound immunoglobulin (Ig). B cells are identified by their 
expression of CD19, a marker that, unlike the incorporation of CD3 in the TCR on T cells, 
is not incorporated into the BCR on B cells. Instead, it resembles the function of CD4 and 
CD8 in T cells, since it strengthens the B cell activation cascade when engaged. CD19 
forms, together with CD81 and CD21, the B cell co-receptor complex (Figure 6).4, 5  
 
A B cell’s main function is to produce and secrete antibodies, which are essentially soluble 
Igs. Antibodies recognize pathogens directly and not via HLA(-like) molecules like T cells 
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do. Antibodies can be seen as a combination of two heavy chains and two light chains 
(Figure 6). During a process called somatic recombination, B cells rearrange their heavy 
and light chain gene segments and start to express a large variety of potential heavy and 
light chains, somewhat similar to TCR gene rearrangement. Similar to T cells, the 
rearrangement of the heavy and light chains is random. This creates a vast variety of B cells 
with different heavy and light chains, but a single B cell will only produce a single 
combination of the chains, producing a single specific antibody.4, 5  
Antibodies can also be split into a variable and a constant region. The variable region 
recognizes the pathogen and is formed by both the light chain and the top part of the heavy 
chain. Since a large number of combinations of heavy and light chains are possible, the 
variable region varies dramatically between B cells. B cells can thus recognize a large 
number of pathogens.4, 5 
 
The constant region determines the antibody class or isotype, and is formed by the lower 
part of the heavy chain. There are 5 Ig isotypes; IgA, IgD, IgE, IgG (which has 4 subclasses 
of its own: IgG1, IgG2, IgG3 and IgG4), and IgM. The Ig isotype determines its function 
and efficacy. For instance, IgM, IgG1 and IgG3 can start the classical pathway and IgA the 
alternative pathway of complement activation.35 IgE is involved in defence against 
multicellular parasites but also plays a role in allergy.36 While B cells may always produce 
the same antibody in terms of the pathogen pattern they recognize, during development and 
B	cell	receptor	
complex
B	cell	co-receptor	
complex
light	chain
heavy	chain
antigen	binding	 site
Igβ Ig!
CD81
CD19
CD21
Figure 6. Schematic of the B cell receptor complex (BCR) and the B cell co-receptor complex. The BCR, consists of an 
immunoglobulin which can recognize and bind a specific pathogen antigen. The associated Iga and Igb will start the 
signalling cascade to activate the B cell after the immunoglobulin binds its antigen. The B cell co-receptor complex 
consists of a CD81, CD19 and CD21 receptor. After CD21 binds to complement C3dg coated on the pathogen surface, 
the B cell co-receptor complex clusters with the BCR. This phosphorylates CD19 and initiates downstream signalling to 
enhance cell activation. The role of CD81 is as of yet unknown. 
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activation they can and will switch isotypes. This isotype switching ensures a more efficient 
response adapted to the specific pathogen.4, 5  
 
B cell development and activation are quite different compared to T cell development. One 
main difference is the site of development. B cells start their development in the BM, where 
they will stay until they become mature naïve B cells and are released into the periphery. 
They continue their education and development in lymphoid tissues, influenced by CD4+ T 
cells and dendritic cells. Since B cell development is not directly dependent on the thymus, 
new mature naïve B cells are continuously formed throughout life.  
 
B cells have the same progenitor as T and NK cells, however, they mature in the BM. The 
common lymphoid progenitor either leaves the BM towards the thymus to become a T cell, 
or it interacts with the stromal cells in the BM, directing the cell to go down the B cell 
developmental pathway. During B cell development, the B cell migrates through the BM 
and progresses through the following steps; early pro-B cell, late pro-B cell, large pre-B 
cell, small pre-B cell, immature B cell and finally a mature (naïve) B cell. During these 
stages, random heavy and light chain rearrangement takes place. If the B cell is incapable of 
forming a stable heavy and light chain combination, the B cell will undergo apoptosis. 
During development, B cells are in constant contact with the stromal cells until they reach 
the stage of immature B cell. Similar to T cells, B cells need to undergo negative selection. 
Potential autoreactive B cells must be eliminated as they otherwise can cause harm to our 
bodies. This process is called central tolerance, as the B cells are tested for autoreactivity in 
the BM, a central lymphoid organ. Some autoreactive B cells may escape this process and 
move towards peripheral lymphoid organs. Luckily, B cells can also be removed here 
through the process of peripheral tolerance. Ultimately, the aim is to have cells capable of 
recognizing pathogen antigen and not self-antigen. If an immature B cell survives the 
central tolerance process, the cell continues to mature and will leave the BM. The mature 
naïve B cell now displays both IgM and IgD on its surface. The B cell will need to be 
activated before it can produce other isotypes.37-40 
 
After leaving the BM, the mature naïve B cell moves into the peripheral lymphoid organs 
where it can interact with dendritic cells. After a mature naïve B cell has encountered its 
antigen on a dendritic cell, the B cell internalizes the antigen-Ig complex and starts to 
display the antigen on HLA class II receptors.4, 5 The B cell can now interact with CD4+ T 
cells. It needs to do so in order to receive additional signals required for activation. If it 
does not interact with a CD4+ T cell within 24 hours it will go into apoptosis. The B cell 
and the CD4+ T cell recognize the same antigen and begin to interact. They migrate 
together to a specific location in the lymph node and start to clonally expand forming so-
called germinal centres.41 Depending on the interaction with CD4+ T cells (production of 
certain cytokines), B cells will switch the constant region of their Igs. This leads to a 
change in isotype class, a process called isotype switching. Moreover, unlike T cells, B 
cells can also diversify the variable regions of their Igs. This is done through somatic 
hypermutation and gene conversion. They both alter the variable region of an Ig leading to 
an altered recognition of the antigen. Somatic hypermutation introduces point mutations in 
the heavy and light chain variable regions, while gene conversion will replace entire 
segments of the variable region with segments from variable regions of certain 
pseudogenes. The end result will affect the B cell antibody affinity for the antigen, with 
some binding better and others worse. Due to competition for available antigen, B cells 
with antibodies that bind better will outcompete the other B cells. Thus, the B cells with 
optimized antibodies survive.42, 43 This entire process of T-B cell interaction usually starts 
days after primary infection and lasts for several more days. Therefore, it takes between 1-2 
weeks after initial primary infection before a robust B cell response is in place.4, 5  
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After the B cells have been activated, expanded and optimized, they either become memory 
B cells or plasma cells. Plasma cells migrate back towards the BM and essentially become 
antibody-secreting factories. These cells continuously secrete antibodies and function as a 
line of defence for a recurring pathogen invasion until they ultimately die.44 The central 
memory B cells migrate from lymph node to lymph node in search of a new invasion of the 
same pathogen. They will be able to expand and react to a new infection more quickly and 
efficiently the second time as they no longer need to undergo isotype switching or increase 
their specificity.4, 5 
 
B cells fight pathogens by coating the pathogen of interest with secreted antibodies. B cells 
secrete antibodies, which then circulate in the blood and lymph in search of a pathogen they 
can bind. If a pathogen is found, the antibodies bind to its specific target on the surface and 
start to coat it. This coating has multiple effects (Figure 7). First, coating the pathogen with 
antibody may make it impossible for the pathogen to further infect other cells or for a toxin 
to be toxic. This is called neutralisation. Secondly, the coated antibodies also make the 
pathogen more easily recognizable for macrophages and neutrophils. When coated, the 
pathogen is more easily phagocytosed and killed by these cells through the process of 
opsonisation. Lastly, the antibodies coated to the surface of the pathogen may attract certain 
proteins of the complement system. Complement proteins are an additional pathway to 
phagocytosis as an accumulation of complement proteins on a pathogen is also attractive 
for phagocytes. Moreover, the complement system can ultimately create holes in the 
surface of the pathogen, thus killing it. Larger parasites which cannot be phagocytosed can 
be killed in this manner. B cells and their antibodies are thus vital for the elimination of 
extracellular pathogens.45 
 
In conclusion, during activation, B cells go through a process where they recognize their 
pathogen antigen better and better. This is a major difference compared to T cells. After a T 
cell has finished education in the thymus, the T cell has reached its maximum potential to 
recognize antigen. A mature B cell can improve its antigen recognition after encountering 
its antigen.  
B	cell
Complement	 activation
Neutralisation
Mature	
naïve	B	cell
Pathogen
Opsonisation
Figure 7. Schematic representation of the function of B cells. 
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1.1.3 When the System is Broken 
For our continued survival, we all need a well-functioning immune system. For the immune 
system to work correctly, it needs to be able to discriminate between “self” and “non-self” 
as well as “normal” and “non-normal”. Unfortunately, it occasionally happens that the 
immune system struggles with this discrimination.  
 
An example of this can be seen in the form of autoimmunity disorders, such as rheumatoid 
arthritis. In autoimmune disorders, a patient’s immune system mistakes healthy normal 
cells for foreign or non-normal cells and attacks, resulting in the destruction of perfectly 
healthy tissue.46 The reverse is also possible, the immune system fails to recognize non-
normal cells or is incapable of destroying the non-normal cells, leading to a proliferation of 
cells that should not be there. This is what happens in cancers (in simple, broad terms).47 
Some people are even born with a deficiency in their immune systems; e.g., primary 
immunodeficiency disorders (PIDs). The immune system in these patients is severely 
impaired.48  
 
There are also other things that can influence the proper functioning of the immune system. 
For instance in the case of human immunodeficiency virus (HIV). HIV does not result in 
the death of patients directly, instead, people die from common pathogens. Normally, these 
pathogens would be no problem for the immune system to handle. However, in the case of 
HIV, the immune system is compromised as the patients’ CD4+ T cells are infected and 
destroyed by the virus, resulting in very low frequencies of this vital cell type. The patient’s 
adaptive immune system is therefore reduced in function and is heavily compromised in its 
ability to eliminate common pathogens.49 
 
So far, these examples have all been natural causes for immune impairments. It is also 
possible to impair an immune system in a more man-made way; irradiation. After the 
nuclear bombs on Nagasaki and Hiroshima at the end of the Second World War, survivors 
were exposed to large doses of radiation caused by the fall-out of the bombs. As a result, 
their immune systems were almost completely destroyed. With the cold war starting and 
people fearing a global nuclear war, scientists started exploring ways of transplanting 
immune systems from a donor to a patient whenever a patient was exposed to very high 
levels of radiation.50 Such an immune system transplantation is more accurately termed a 
hematopoietic stem cell transplantation (HSCT). The entire hematopoietic system is 
transplanted, which includes all blood cells and not just immune cells (Figure 1). 
 
Coincidentally, nuclear bombs were not the only cause for irradiation. Clinicians had also 
been experimenting treating malignancies, such as cancers, with irradiation. All of this 
research led to the start of the field of HSCT and transplantation immunology. 
 
 
1.1.4 Transplantation Immunology 
Nowadays, transplanting organs or hematopoietic stem cells from a donor to a patient is 
done on a regular basis in many hospitals across the world. Most countries even advertise 
voluntary donor programs. However, transplantations were at one point experimental and 
dangerous. Fine-tuning transplantation procedures has taken time. Since the start of this 
field in the 1960s, there has been a significant research effort to better understand 
transplantation immunology. For instance, we now know that we cannot indiscriminately 
place any donor’s organ into any patient. We need to “match” donor and patient for certain 
variables, how stringent depends on the organ or tissue transplanted. This necessity of 
matching comes down to immunology.  
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The immunology behind transplantation is complicated. The most important factor in 
transplantation immunology is the fact that immune systems are trained to recognize “self” 
from “non-self”. By definition, a donor’s organ is “non-self” and will be attacked by the 
patient’s immune system if left to its own devices. Similarly, in a HSCT, the entire patient 
body is seen as “non-self” by the transplanted donor immune system.  
 
The consequence is that patients who receive a donor solid organ (liver, kidney, heart, etc.), 
will usually have to take lifelong immunosuppressive drugs to keep their immune systems 
from attacking and rejecting the new “non-self” organ.51 Physicians have to balance 
suppressing the patient immune system to not reject the transplanted solid organ while 
allowing sufficient leeway for the immune system to function so patients do not get 
terminally ill from common pathogens. For HSCTs this works slightly different, yet similar 
in many ways, and will be explained in detail in the next sections.  
 
 
 
 
1.2 HEMATOPOIETIC STEM CELL TRANSPLANTATION 
 
1.2.1 Rationale & History 
As mentioned earlier, scientists first started to consider HSCTs after the two nuclear bombs 
were dropped over Japan at the end of the Second World War. Clinicians were trying to 
treat patients who were severely immunocompromised, anaemic and thrombocytopenic due 
to the high radiation. At the same time, they realized that the ability to rescue these patients 
could be an extremely valuable treatment option for patients with malignancies like cancer. 
Cancer treatment at the time was hampered by the fact that clinicians could only irradiate 
patients to a certain level lest their hematopoietic system became too heavily compromised 
resulting in patient death. This meant that treatments were often inefficient as cancers came 
back. If they could find a way to cure patients with almost no remaining hematopoietic 
system, they would be able to irradiate patients with cancers to a much higher degree.  
 
The first HSCT experiments were performed on animals, mostly in mice and dogs, in the 
1950s and early 1960s.52, 53 In the late 1950s and 1960s, the first trials on humans were 
done.50, 54 At that time the HLA system was not yet discovered. Unsurprisingly, patients 
who were transplanted in this early era of HSCT did not survive for long. Main causes of 
death were graft failure, graft-versus-host disease (GVHD), relapse and infections, all of 
which will be explained in detail later on.54, 55 Due to the disappointing results, the field 
stagnated and not many HSCTs were performed on humans.  
 
However, after the scientific community learned more about the immune system and 
specifically about the HLA system56, HSCTs were performed increasingly often. Several 
landmark achievements (for instance the discovery of immunosuppressive drugs like 
cyclosporine) further improved survival rate and ultimately increased patient quality of life. 
HSCTs were becoming an established treatment option. Since the 1970s the field has thus 
been steadily growing, especially so during the last few decades. Improved HLA-typing 
methods, larger donor registries, more diverse conditioning regimen options, better 
immunosuppressive regimens and better supportive care have all contributed to that 
effect.57 Currently, worldwide around 50.000 HSCTs are performed annually, curing a 
variety of disorders (www.who.int).58  
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1.2.2 Indications 
The first disorders which were attempted to be cured by HSCT were mostly of a malignant 
nature, namely acute leukemias. However, HSCT was also quickly indicated for patients 
suffering from non-malignant disorders such as severe aplastic anaemia and severe 
combined immunodeficiency.59, 60 
 
Currently, a large variety of both malignant and non-malignant disorders are treated with 
HSCTs. The vast majority of HSCTs worldwide are still done for malignant disorders, of 
which leukemias remain the most common.61 The classification of leukaemia depends 
primarily on the developmental stage and lineage of haematopoiesis the leukemic cell is 
from. Acute myeloid leukaemia and chronic myeloid leukaemia both originate from the 
myeloid lineage. There are also leukemias that originate from the lymphoid lineage; acute 
lymphoid leukaemia and chronic lymphoid leukaemia (CLL).62 CLL is also often referred 
to as B-CLL, as in this form of leukaemia the B cells are affected. These four leukemic 
types have several subtypes, mostly classified by genetic markers, but we will not go into 
depth about these variants. While these four leukemic types are the most common 
malignant disorders that can be cured by HSCT, there are several other malignancies for 
which patients are transplanted. These are for instance, myelodysplastic syndrome, 
lymphomas, multiple myeloma and several solid tumours.61, 63, 64  
 
While malignant disorders are clearly lethal diseases if left untreated, non-malignant 
disorders are, despite the perhaps misleading name, also lethal in many cases, otherwise 
they would not warrant a HSCT, with its potential serious complications to be performed. 
Non-malignant disorders are generally divided into PIDs, non-malignant hematologic 
conditions and inborn metabolic disorders. These disorders can often only be cured with a 
HSCT. Though not exclusive to children, the vast majority of patients transplanted for non-
malignant disorders are children or young adults. This is because most non-malignant 
disorders are present from birth. Some examples of non-malignant disorders that could be 
treated by HSCT are sickle cell anaemia, thalassemia, severe aplastic anaemia, Fanconi 
anaemia, Wiskott-Aldrich syndrome, and even severe forms of Crohn’s disease.61, 63-66 
 
 
1.2.3 Procedure 
The decision whether to perform a HSCT is based on an individual patient assessment. 
Factors such as age, comorbidities, prior treatment, remission status and underlying 
disorder are examples of facts that must be taken into account. As HSCT is a high risk high 
reward endeavour, risk-benefit ratios must be considered for each patient.  
 
While HSCT is a well-established technique performed in many countries, procedures are 
complicated and vary between centres. This section is an attempt at illustrating some of the 
aspects of HSCT procedure, though, due to space restrictions, not all aspects are touched 
upon. Aspects most vital for the understanding of HSCT in general and for the research 
performed in this thesis have been prioritized. 
 
In short, the procedure for a HSCT is as follows. Hematopoietic stem cells are harvested 
from a healthy living donor. The patient undergoes a conditioning regimen and the donor 
hematopoietic stem cells are infused as a transfusion into the patient’s blood stream. The 
patient is then monitored closely for early treatment and transplant-related complications 
and if all goes well, the patient should be able to go home after a few weeks. However, the 
continuous follow-up at a specialized open-clinic is usually life-long, even if visits may be 
less frequent over time if the post-HSCT period continues to be uneventful and free from 
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severe complications. For a simple graphical representation of the HSCT process, please 
see Figure 8. Of course, much more goes into a successful HSCT. Some of the details of 
each of these aspects will be discussed in detail in the next sections.  
 
1.2.3.1 Conditioning 
Before a HSCT can be performed, the patient undergoes a conditioning regimen to prepare 
him/her for HSCT. The thought behind conditioning is to reduce the patient’s own 
hematopoietic system, to suppress remaining immune cells and to eradicate the malignancy. 
Another argument for conditioning is the belief that space needs to be created in the 
patient’s BM for the infused donor cells to engraft. This belief is heavily debated and 
remains controversial.67  
 
Donor Patient
Transplantation
Conditioning Prophylaxis
MAC/RIC
Chemotherapy
Irradiation
Sensitive	for	Infections
Neutropenic
Isolation	of	patient
Day	01-2	weeks	pre-HSCT Several	months	post-HSCT
Infusion	of	graft	
hematopoietic	 	
stem	cells
Figure 8. A schematic of the HSCT procedure. A patient undergoes a conditioning regimen for 1-2 weeks. At day 0, 
the day of HSCT, hematopoietic cells are harvested from the graft, be it bone marrow, peripheral blood or cord 
blood, and infused into the patient. During the months post-HSCT, the donor graft needs to take hold, during which 
the patient is at increased risk of infections and other complications. Often the patient is isolated or shielded in 
some form in the hospital or at home during this period. 
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Conditioning regimens can vary in drugs used, irradiation used and duration. Choosing the 
regimen depends on factors such as age and physical wellness of the patient, the underlying 
disorder, the experience and preference of the centre where the HSCT is performed and 
many more. An ideal conditioning regimen enables a quick engraftment of the donor cells, 
minimal toxicity for the patient and maximum elimination of the malignant cells in patients 
with malignancies. In broad terms, conditioning regimens can be divided into 
myeloablative conditioning (MAC) and reduced intensity conditioning (RIC) regimens.68 
 
MAC regimens are generally considered to be more intense and harsh for patients. These 
regimens usually consist of high doses of chemotherapy with and without irradiation. 
Patients undergoing MAC become severely immunocompromised and will not survive 
without HSCT. They are often used in relatively fit patients who have a malignant disorder. 
In these cases, it is vital to eliminate as much of the underlying malignancy as possible. 
MAC regimens are also sometimes preferred for non-malignant disorders, as RIC regimens 
are associated with an increased risk of graft rejection. Moreover, patients with non-
malignant disorders are quite often children who can handle tougher regimes than elderly 
patients. MAC regimens traditionally made use of total body irradiation (TBI) and the drug 
cyclophosphamide (Cy). While various combinations of drugs have been tried, the majority 
of MAC regimens nowadays follow the Cy/TBI, etoposide(VP-16)/TBI or busulphan 
(Bu)/Cy regimen.69, 70  
 
RIC regimens were developed during the 1990s, and are usually considered less intense. 
They were developed to reduce the patient toxicity associated with MAC regimens, while 
retaining the beneficial effect of the graft-versus-tumour (GVT) effect of the infused donor 
hematopoietic cells. The development of RIC regimens enabled elderly patients as well as 
those with more comorbidities to potentially receive a HSCT. RIC regimens often do not 
include irradiation or only low amounts of fractionated TBI and reduced doses of 
chemotherapeutic drugs. Patients who undergo this regimen often have low levels of 
remaining hematopoietic cells, including defect or malignant ones, left at the day of 
transplantation. The infused graft will need to eliminate any remaining cells. If necessary, 
donor lymphocyte infusions (DLI) can be given to aid. Most RIC regimens include 
fludarabine (Flu). Common RIC regimens are Flu/Bu, Fly/Cy and Flu/TBI regimens.69, 70 
 
 
1.2.3.2 Grafts  
So far we have assumed that the transplanted graft came from a donor, a so-called 
allogeneic HSCT. It is also possible to perform a HSCT where the transplanted 
hematopoietic cells originate from the patient themselves, called an autologous HSCT. 
Autologous grafts derive from the patient themselves, hence, there are no problems with the 
transplanted immune system reacting in a negative manner. However, an autologous HSCT 
does not cure a genetic disorder, as the deficiency will still be present (in the patient/the 
graft). Moreover, in malignant disorders a recurrence of the malignancy after HSCT is a 
major risk.71 In this thesis, the focus is on allogeneic HSCT and we will therefore not 
discuss autologous HSCT in any further detail.  
 
Allografts for HSCT can be obtained from different sources. Traditionally, grafts were 
extracted from the BM of donors. Hence the more commonly used lay term of “bone 
marrow transplantation” instead of HSCT. Since hematopoietic stem cells are located in the 
BM, they are a perfect graft source. However, BM harvesting is an invasive, painful 
procedure and not without risk for the donor. For instance, donors need to undergo general 
anaesthesia for the operation.72  
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Nowadays, the majority of HSCTs are not performed with a BM graft, instead mobilized 
peripheral blood stem cells (PBSCs) are used.61 A donor is treated for several days with 
granulocyte colony-stimulating factor (G-CSF), which stimulates the hematopoietic stem 
cells to migrate from the BM into the peripheral blood.73 The donor then undergoes an 
aphaeresis for collection of the allograft. This procedure is less painful, less risky, less time 
consuming and no surgery nor anaesthesia is required. Moreover, PBSC grafts lead to faster 
reconstitution and have an enhanced GVT effect compared to BM grafts. However, PBSC 
grafts have been coupled to an increased risk of GVHD in some studies, though not all.74-77 
(The GVT effect and GVHD will be explained in detail in later sections.) Hence, in cases 
where the GVT effect is not important and the risk of GVHD should be reduced, for 
instance in non-malignant disorders, a BM graft is still slightly preferred.61 However, some 
centres may opt to ask paediatric donors to donate PBSC and not BM, especially when 
donating to an adult patient, to avoid some of the difficulties in obtaining sufficient BM 
sample and to reduce the risk for the donor.  
 
A third option for graft collection, umbilical cord blood (CB), has quite recently emerged, 
although with some mixed results.78, 79 After birth, a substantial amount of fetal blood 
remains in the discarded umbilical cord. This CB is enriched in hematopoietic stem cells 
and if parents consent, can be harvested and stored for future use in HSCTs. These CB 
grafts are stored in massive CB banks and can be bought and used for HSCTs. A major 
disadvantage of these CB grafts is that the volume and hematopoietic stem cell content is 
usually quite small/low compared to BM and PBSC grafts, and can therefore often only be 
used for children or young adults. Some centres have attempted to perform double CB 
transplantations where two different CB grafts are transplanted to increase the 
hematopoietic stem cell content. Usually in those cases, only a single CB graft will 
eventually engraft and repopulate a patients BM, though in rare cases both CB grafts may 
survive.80 Additionally, it is not possible to go and ask the respective donor for additional 
cells if necessary, as is possible in the case of conventional BM or PBSC allografts.  
 
The possibility to ask a donor for more cells at a later time point is also one of the reasons 
why clinicians will investigate whether a family member could act as a potential donor. 
However, more importantly, family members are also much more likely to be similar for 
the major as well as the minor HLA histocompatibility antigens. As discussed earlier in the 
introduction, siblings have a 25% chance of having the same HLA-alleles. Unfortunately, it 
is quite likely that there is no suitable relative to act as a donor. Therefore, most current 
HSCTs are performed using unrelated volunteer allografts, with good results.81 These 
donors volunteer themselves altruistically to give cells to patients they have never met.  
 
In general, clinicians will try to locate a donor who matches the patient’s major HLA alleles 
as best as possible. Some HLA alleles are thought to play a more important role than others. 
Therefore, centres will try to match between 8 to 12 HLA alleles. High resolution typing is 
usually done for HLA-A, HLA-B, HLA-C (HLA class I alleles) and for HLA-DRB1, HLA-
DQB1, and HLA–DPB1 (HLA class II alleles), since these are considered to vary the most 
between individuals. In the end, grafts are termed to be fully matched or mismatched, when 
1 or 2 HLA alleles differ.82 A mismatched graft is sometimes the only option if no fully 
matched donor is found.  
 
A relative new phenomenon is the haploidentical allograft. In this case, usually a parent or 
child is the donor for the patient and, as such, only half the HLA loci will match, but both 
for the major as well as the minor HLA histocompatibility antigens. The patient thus 
receives only one HLA haplotype, hence the name. The validity of this type of graft 
remains under debate but has shown great potential.83 Since parents or children may act as a 
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haploidentical donor, the donor pool will increase dramatically. Moreover, as haploidentical 
donors are more likely to live in the same area as the patient, transport time will be reduced, 
leading to higher graft quality and viability. Thus, if haploidential allografts are proven to 
be a viable option, more patients will be termed eligible for HSCT. This would reduce the 
turnaround time for HSCTs. 
 
Lastly, as most grafts are from volunteers, they are usually harvested in other centres and 
need to be transported. In some cases, the grafts are even flown in and will be underway for 
more than a day. Some studies have linked transport time and the environment in which the 
graft is placed during transport to HSCT outcome.84-86 Thus, attempts are made to keep 
transport related factors between certain standards.  
 
In the end, choosing a donor is mostly based on HLA disparity. However, many other 
factors, such as AB0 blood group matching, human cytomegalovirus (CMV) serology, 
donor and patient gender, donor age and geographic location may all influence the choice 
of a donor graft. 
 
 
1.2.3.3 Prophylaxis 
After selecting a donor and after the patient has undergone conditioning, the allograft is 
harvested and infused into the patient. This is referred to as “day 0”. Due to the 
conditioning regimen, the patient is now severely immunocompromised. The new 
hematopoietic system needs time to reconstitute and is unable to protect the body against 
pathogens during this time. To support the immune system during this time, patients 
receive prophylactic antimicrobial drugs and specialized nursing routines to prevent excess 
toxicity from the conditioning (e.g. mucositis) and infections.87-91 
 
Patients also receive prophylactic immunosuppressive drugs to prevent the donor’s immune 
system from attacking healthy tissue, the complication called GVHD. This will be 
explained in more detail in later sections as a large part of the research presented revolves 
around GVHD. Some of the more common prophylactic treatments against GVHD include 
a calcineurin inhibitor (cyclosporine or tacrolimus) in combination with a short course of 
methotrexate, and in some transplant settings anti-thymocyte globuline (ATG).92 Current 
treatment protocols are far from perfect and research into new prophylactic drugs and/or 
new combinations of drugs or supportive care is continuously ongoing.93, 94 It is one of the 
main topics in many clinical HSCT trials. 
 
 
1.2.3.4 Reconstitution 
After HSCT, the new donor-derived immune system is impaired both quantitatively and 
qualitatively. It needs time to engraft and expand. During this time period a patient does not 
have a fully functional immune system and is vulnerable to various infections; 
opportunistic, community acquired or nosocomial. In a successful HSCT the donor-derived 
hematopoietic cells will engraft and reconstitute the patient BM, ultimately forming a fully 
functioning immune system. The process of forming a new immune system is called 
immune reconstitution and, depending on the cell type, can take months to years post-
HSCT to be completed.95, 96 Conditioning regimens, stem cell source, patient age and viral 
infections can also all influence the reconstitution process.97 For instance, PBSC grafts 
reconstitute faster than BM grafts, administration of ATG in the conditioning regimen may 
delay reconstitution and elderly patients may reconstitute later as they often have an 
involuted thymus compared to younger patients.98 
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Cells from the innate immune system reconstitute faster than those from the adaptive arm. 
This is primarily because cells from the innate system do not require the same extensive 
rearrangement and education processes to achieve full effector functions. For instance, 
neutrophils engraft and repopulate to normal peripheral cell quantities just 2-4 weeks post-
HSCT. In fact, neutrophil engraftment is often used as a clinical measure and indication of 
overall donor engraftment. NK cells usually take up to 1-3 months to return to normal 
levels. T and B cells from the adaptive immunity take much longer, and reconstitution can 
take from 3 months up to 1-2 years or longer, with persistent (or at least prolonged) deficits 
in terms of global immunity. T cell immune reconstitution can be thymus-dependent and 
thus monitored by examining thymic output by assessing TREC levels in the blood. It can 
also be thymus-independent, where circulating cytokines and viral infections may activate 
and drive expansion of memory T cells co-infused with the graft.99 The latter mechanism 
usually occurs faster post-HSCT, while the first may take up to a year or more. The gd T 
cells seem to reconstitute faster than the normal ab T cells, after approximately 1-2 months. 
Interestingly, the TCRgd repertoires appear to be heavily skewed towards a response 
directed against viral infections.100 B cell reconstitution usually takes up to 1-2 years and is 
often influenced by chronic GVHD development.90, 101-105 
 
In general, for most patients a fully reconstituted immune system post-HSCT can take up to 
2 years. During this time, patients need to be extra careful in their daily interactions and 
activities to avoid infections that healthy individuals would have no problems combating. In 
line with this, patients will need to be revaccinated after immune cell levels have 
reconstituted to semi-normal levels.90, 96 
 
 
1.2.3.5 Graft-versus-Tumour 
While we do not want donor-derived immune cells to attack healthy recipient cells, we do 
want donor-derived cells to eliminate any remaining tumour cells. Especially in the case of 
RIC conditioning regimens, not all tumour cells are eradicated when transplantation takes 
place. This desired effect of donor cells attacking tumour cells is called the GVT or graft-
versus-leukaemia effect.106, 107 
 
The mechanism behind this effect is the simple way immune cells recognize the tumour 
cells as non-self and non-normal, triggering effector actions against such cell populations. 
After transplantation, clinicians must find a careful balance, stimulating GVT but not 
GVHD. In fact, as these are so closely related, there are many centres in which a low-grade 
GVHD early post-HSCT is actually desired in patients transplanted for malignant 
disorders.108  
 
However, over promoting GVT may result in severe GVHD which can be fatal for the 
patient. Therefore, patients are also immunosuppressed. Administrating a heavy 
immunosuppressive treatment will impair the GVHD response, but also the GVT effect, 
and as such will increase the risk for malignant relapse. Hence, it is a constant struggle to 
balance GVT and GVHD and new research into enhancing GVT while reducing GVHD is 
ongoing.109-113 
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1.2.4 Complications 
Being the only curative option for many lethal or severe disorders, HSCT remains a 
treatment that can come with a steep price for patients after treatment, both in terms of 
morbidity and mortality. A large number of complications can occur during the first 
months, even years, post-HSCT (Figure 9). While a large amount of research on HSCT is 
focused on preventing and treating these complications, and successful progress has been 
made over the past decades, they are unfortunately still a major part of HSCTs.114 In fact, 
half of the research presented in this thesis revolves around better understanding some of 
these complications.  
 
1.2.4.1 Infections 
Due to previous disease treatment and conditioning regimens, patients are severely 
immunocompromised initially post-HSCT. During this time, patients experience 
neutropenia and abnormally low levels of lymphocytes in the blood. The donor-derived 
immune cells need time to expand. During the reconstitution, patients have an increased 
risk for a variety of infections. The most common infections are of viral origin, specifically 
human herpesviruses such as Epstein-Barr virus, CMV, varicella zoster virus (VZV) and 
herpes simplex virus. These are all viruses a large percentage of us continuously have in 
our bodies in a latent state, kept controlled by our fully functioning immune system. 
However, as soon as an individual is immunocompromised, these viruses “awaken” and can 
become a potential threat.115-117 For this reason, patients may receive prophylactic antiviral 
drugs.  
 
Bacterial infections are also a problem, though usually to a lesser degree than viral 
infections. This is partly because broad spectrum antibiotics are readily available and the 
neutrophil granulocytes reconstitute rapidly post-HSCT. However, treatment has to be 
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Figure 9. A schematic representation of some of the most common complications post-HSCT. 
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initiated quickly as patients cannot mount an effective immune response on their own early 
post-transplantation. This is mostly because the low levels of effector immune cells, the 
immunosuppression and the damage of the conditioning regimens all make life easier for 
the bacteria.118-120  
 
Lastly; fungal infections, which can be extremely difficult to treat. They usually manifest in 
the lungs as fungal spores are often airborne and drawn in by breathing. With limited T cell 
numbers and repertoire, antifungal drugs are the only treatment option. Therefore, it is 
critical that these patients avoid exposure to fungi and spores during the neutropenic phase. 
During this time, patients are generally treated with isolation routines and are, for instance, 
instructed to not directly contact soil, go near construction sites, or be in buildings 
undergoing renovation.117, 121  
 
 
1.2.4.2 Rejection/Graft Failure/Relapse 
Another complication that can occur is rejection of the donor-derived allograft. This occurs 
when there are remaining recipient immune cells after conditioning which eliminate the 
infused donor cells. The donor-derived cells are killed and the graft is rejected by the 
recipient quite like how an organ can be rejected after solid organ transplantation. This 
leaves the patient without a fully functioning immune system. If a graft cannot take hold, 
the patient is at an increased risk for infections and of relapse, potentially allowing the 
malignancy to return in full force. The malignant cells are then even more threatening, as 
the conditioning effectively killed of any remaining recipient immune cells providing 
protection against the malignancy.122, 123  
 
Fortunately, clinicians can often see a threatening relapse while it is still in its early stages. 
Patients can be monitored for the presence of donor- and recipient-derived cells in blood 
and BM, called chimerism analysis. If this analysis detects increasing amounts of recipient 
cells in the blood or BM over time, it indicates that recipient cells are outnumbering the 
donor-derived cells. In patients with a malignancy this almost always suggests a relapse of 
the malignancy.124-126 However, it could also indicate graft rejection as chimerism results 
are relative and not absolute. For instance, if the donor-derived cells are killed by the 
recipient cells, the frequency of recipient cells will increase dramatically, but this is due to 
removal of donor-derived cells and not an increase of recipient cells. Therefore, absolute 
blood counts are considered when deciding if a patient faces a graft rejection or relapse. 
 
Often, if an allograft rejection or relapse is detected before it is fulminant, steps can be 
taken to stop its progression and to turn the path back to engraftment of the donor cells. In 
those cases, the immunosuppression can be modulated or a patient can receive DLIs. These 
are in essence donor hematopoietic cell boosts. The DLIs will increase the number of 
donor-derived hematopoietic cells in the patient and can hopefully turn the tide in favour of 
the donor-derived immune system.127-129 However, in some cases DLIs are unable to 
prevent graft rejection or relapse.130 In such cases, the only option is to perform a re-
transplantation, either with the same donor as before or with a new donor.131-134  
 
 
1.2.4.3 Acute GVHD 
Even though patients and donors are matched as well as possible for HLA alleles, a match 
will never be 100%. Even if the donor is an identical twin of the patient, some small 
histocompatibility mismatches will still be present. Unfortunately, because immune cells 
are trained to attack cells displaying non-self antigens, there is always a risk that the 
  25 
immune cells derived from the donor graft will attack patient cells (interpreted as non-self). 
If donor cells attack remaining tumour cells, it is seen as a good thing. However, if the 
patient cells under attack are not tumour cells but are healthy, a serious complication arises. 
This is what happens in GVHD. If left untreated, GVHD can be lethal. Clinicians therefore 
face a dilemma, beneficial GVT versus harmful GVHD. How do you promote one and 
prevent the other? But first, we need a better understanding of the biology of GVHD.  
 
In many ways GVHD can be thought of as an extreme form of autoimmunity. The immune 
system attacks the body itself. However, in GVHD, the body is not the body of the immune 
system, it is the body of the patient/recipient, hence, it is not an autoimmune disorder in the 
strictest sense of the word. 
 
To better specify GVHD, Billingham set forth the following requirements for GVHD to 
occur.135  
 
1. The graft must contain immunologically competent cells. 
2. The recipient must express tissue antigens that are not present in the transplant 
donor. 
3. The patient must be incapable of mounting an effective response to eliminate the 
transplanted cells. 
 
In essence, this means that a transplanted allograft must be capable to become activated and 
must be able to distinguish patient cells as non-self. Moreover, the patient immune cells 
must be unable to mount a response towards the graft. If these 3 conditions are met GVHD 
can develop. 
 
In broad terms, GVHD comes in two flavours: acute and chronic. However, the world is 
seldom black and white, there are many shades of grey and GVHD is no exception. I will 
start to explain GVHD by discussing acute GVHD (aGVHD) as this is the form that may 
occur first post-HSCT. Then I will discuss the in-between forms of GVHD (e.g. late onset 
aGVHD and overlap syndrome) to end with chronic GVHD (cGVHD) in the next section. 
 
Acute GVHD arises within the first 3 months post-HSCT, by strict definition (Glucksberg 
criteria).136, 137 Most patients start to present signs of aGVHD within 2 weeks to 2 months 
post-HSCT. 
 
Table 1. Staging of aGVHD according to the Glucksberg criteria. 
Grade 
Clinical symptoms 
Skin 
(maculopapular rash) 
Liver 
(serum bilirubin) 
GI-tract 
(mL of diarrhoea) 
General clinical 
performance 
I <25% up to 50% of body surface - - - 
II 
<25% of body surface 
up to generalised 
erythroderma 
34 up to 50 µmol/L 500 up to 1000 mL Mild decrease 
III 
25-50% of body 
surface up to 
generalised 
erythroderma 
51 up to 255 µmol/L 1000 up to >1500 mL Moderate decrease 
IV 
25-50% of body 
surface up to 
generalised 
erythroderma with 
bullous formation and 
desquamation 
51 up to >255 µmol/L 
1000 up to >1500 mL 
and severe abdominal 
pain with or without 
ileus 
Extreme decrease 
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A patient can present with different grades of aGVHD severity (Table 1). Grade I manifests 
as skin rashes. Symptoms of grade I aGVHD are usually quite mild and might reflect an 
activated donor-derived immunity which is associated to a GVT effect. Hence, for patients 
with malignant disorders, a grade I aGVHD is often seen as a desirable phenomenon. For 
grade II aGVHD diagnosis, gastro-intestinal (GI) tract or liver involvement is necessary. 
The symptoms in these two organs remain relatively mild at this stage; slightly elevated 
bilirubin levels and medium quantity of diarrhoea. Grade III and IV aGVHD are the highest 
grades, where patients have severe symptoms from their GI tract, liver and skin.138, 139 
Acute GVHD grade III-IV is luckily rare, especially in our centre.93, 140 However, when 
they do occur, these grades can be difficult to treat and are associated with severe morbidity 
and mortality rates.141, 142 
 
Treatment of aGVHD typically consists of varying immunosuppressive regimens. As grade 
I aGVHD manifests as a mild skin rash, topical corticosteroids are usually administered, 
though in some cases systemic corticosteroids may be given too. Patients with more severe 
grades will often receive systemic corticosteroid treatment with varying doses. Treatment 
of grade III-IV aGVHD may also be done by administration of ATG, which eliminates 
circulating T-cells, or other immunosuppressive agents, e.g., methotrexate, infliximab and 
mesenchymal stromal cells.142 A downside of treating patients systemically for aGVHD is 
an increased risk of infections and malignant disease relapse due to general, non-specific 
suppression of the immune system. As such, these patients are closely monitored during 
treatment. Overall, the physicians aim is to strike a balance between suppressing the 
immune system to prevent severe GVHD, while retaining a desired GVT effect and 
manageable infection rates (Figure 10).  
 
While the severity of symptoms is crucial to 
diagnose the grades of aGVHD, in many cases, 
biopsy results of the affected organs are considered 
to support the clinical grading process. Biopsies can 
confirm diagnosis if the symptoms alone are not 
convincing enough.  
 
The pathophysiology of aGVHD is thought to be 
primarily T cell dominated, though many cellular 
subsets are thought to play pivotal roles in aGVHD 
onset and progression, as described in several 
reviews.143-148 Acute GVHD pathogenesis is thought 
to go through three distinct stages. During the first 
stage, remaining patient APCs are activated by the 
vast tissue damage caused primarily by the conditioning regimen. This damage is due to 
radiotherapy, though chemotherapeutic drugs and antibiotics are also known to damage 
healthy patient tissue. Moreover, especially in the GI tract, tissue damage and loss of the 
commensal microbiota may lead to an influx of non-commensal microbes, and subsequent 
release of microbial products, which may further amplify APC activation.149 
 
The APCs will start to display a large variety of self-antigen and varying costimulatory 
molecules in response to the tissue damage. This leads to the activation and proliferation of 
donor-derived T cells. The donor-derived T cells respond to the recipients’ self-antigens as 
well as differences in HLA or minor histocompatibility antigens. For instance, in the case 
of a graft from a female donor to a male patient, the donor-derived T cells may respond to 
the H-Y antigens on (male) host cells.150 Today, over 50 minor antigens that may trigger 
Figure 10. A careful balance between too 
much or too little immunosuppression is 
needed. Too much will increase the risk for 
infections, while too little will increase the 
risk for GVHD. 
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GVHD or GVT have been identified but there is currently no matching performed for these, 
as this would make identifying a donor almost impossible. 
 
The direct cytotoxic effect of the donor-derived T cells and the cytokines they produce 
ultimately leads to the destruction of patient tissue. This destruction leads to more damage 
and APC activation and the process continues in a positive feedback loop. Though not 
cytotoxic on their own, Th1 cells also play a role in aGVHD development. They are known 
to drive and maintain the CD8+ T cell response. Luckily, not only cytotoxic cells are drawn 
towards the inflammation. Tregs are also attracted and attempt to downregulate the ongoing 
process and prevent the alloreaction.144  
 
Classical aGVHD is caused by the primary infusion of the donor-derived allograft. 
However, in a threatening relapse or rejection, a patient may be infused with a DLI to 
enhance the allogeneic effect in the host. In some patients, this infusion may lead to 
aGVHD development, referred to as DLI-induced aGVHD.151, 152 Late onset aGVHD may 
also occur. This is more common in patients undergoing RIC HSCT or when 
immunosuppression is tapered. Overlap syndrome between aGVHD and cGVHD occurs 
when an aGVHD reaction does not end, but instead slowly transforms into a long-lasting 
cGVHD reaction. Patients with this overlap syndrome suffer from symptoms associated to 
both aGVHD and cGVHD. These in between forms can make it difficult to differentiate 
between aGVHD and cGVHD and correctly diagnose the patient.153  
 
 
1.2.4.4 Chronic GVHD 
Patients with cGVHD suffer from a prolonged attack of the donor-derived immune cells 
against healthy patient tissue. In cGVHD, the affected organs and symptoms are quite 
varied. Similar to aGVHD, skin, GI tract and liver are organs often affected, however, 
lungs, joints, eyes, genital areas, mouth, muscles, fascia and other sites of the body can also 
come under attack.154, 155  
 
Traditionally, cGVHD is seen as GVHD with a late onset, often after more than a year to 
several years post-HSCT. However, it can occur as soon as 3 months post-HSCT. Grading 
of cGVHD is similar to aGVHD and is based on clinical symptoms. The NIH criteria are 
used to score cGVHD organ manifestations into a global classification of mild, moderate or 
severe grade. The symptom severity in each of the organ systems affected is scored from 0 
to 3.155 The number of affected organs and their relative classification determines the 
patients cGVHD grade (Table 2). For instance, patients with mild cGVHD present with 
mild symptoms in up to a maximum of 2 different organs, usually predominantly the skin. 
Patients with severe cGVHD will have severe symptoms in more than 3 organs. 
Involvement of the lungs is special, automatically resulting in at least moderate cGVHD. 
Moreover, biopsies can play an important role in diagnosis. Because so many organs can be 
affected in cGVHD, acquiring biopsies may be quite painful for the patient.  
 
Unfortunately, cGVHD is common post-HSCT, occurring in around 50% of all HSCTs and 
even higher in HSCTs with an unrelated donor. Even more troubling is that treating 
cGVHD can be very difficult. Mild cGVHD, similar to grade I aGVHD, can often be 
treated with topical corticosteroids.156 However, moderate and severe cGVHD often need 
long-term systemic corticosteroid treatment and prolonged use of calcineurin inhibitors. 
Unlike aGVHD where systemic immunosuppressive treatment is usually only done for a 
shorter period, patients with cGVHD may be treated with immunosuppressive drugs for 
years. In most patients the dose of immunosuppressive drugs is tapered over time as the 
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patient responds to the treatment. However, some patients never respond to 
immunosuppressive treatment. These corticosteroid-refractory patients have a very poor 
prognosis due to a lack of standard second-line treatment.157 Many research groups aim at 
identifying treatment strategies for treating these patients.158 Even if patients do respond to 
corticosteroids, those with moderate and severe cGVHD will be affected by the disease for 
a long period of time. Therefore, their quality of life is usually reduced.159  
 
Table 2. Staging of cGVHD according to the NIH criteria. 
Grade 
Scoring 
1 organ involved 2 organs involved 3 or more organs involved Lung involvement 
Mild Score 1 Score 1 - - 
Moderate Score 2 Score 2 Score 1 Score 1 
Severe Score 3 Score 3 Score 3 Score 2 
 
While aGVHD is seen as predominantly T cell driven, cGVHD pathogenesis is seen as a 
combination of B and T cell involvement. However, the exact pathogenesis of cGVHD is 
not well understood.154, 160 One major difference between acute and chronic GVHD is the 
extent of damage. While tissue damage in aGVHD is extensive and usually occurs quite 
fast, tissue damage in cGVHD is mostly less extensive and more fibrotic in nature. Since 
cGVHD damage is slower, symptoms may be overlooked for some time. Additionally, even 
if symptoms are quickly diagnosed, treatment is often delayed. Physicians want to be 
certain the cGVHD will progress if left untreated as treatment is correlated to increased risk 
of relapse and infections. 
 
B cells are considered to play a major role in cGVHD. As mentioned, B cell reconstitution 
usually takes longer than T cell reconstitution post-HSCT. At the time of cGVHD onset, B 
cell levels are usually more or less back to normal. During cGVHD, B cell activating factor 
(BAFF), a cytokine vital for B cell survival, is elevated in patient plasma.161, 162 Hence, 
potentially autoreactive B cells that would have undergone apoptosis at normal BAFF 
levels remain alive. These B cells may start to produce autoantibodies that target host 
tissues. Indeed, accumulation of such autoantibodies can be seen in cGVHD affected 
organs.160, 163, 164 
 
The latest research also indicates a role for Th17 cells in cGVHD development, particularly 
of skin lesions. Tissue macrophages which are activated by the GM-CSF and IL-17 
produced by the Th17 cells, will crosslink with the autoantibody coated host tissue cells. 
They will then start to produce cytokines, for instance TGFb, which can explain the fibrosis 
often seen in the affected organs of cGVHD patients to some extent.165, 166  
 
Luckily, similarly as in aGVHD, Tregs are also attracted to the site of inflammation and 
may play a role in dampening the response. However, as Tregs are often found at 
diminished levels in patients with aGVHD and cGVHD, this process is unable to stop the 
inflammatory response on its own. Today, some clinical trials attempt to treat cGVHD with 
adoptive Treg therapy, with some preliminary success.167, 168 
 
As cGVHD is a common late-onset complication of HSCT with severe implications on 
quality of life, research in this topic is ongoing and of utmost importance. 
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1.2.5 Mixed Chimerism 
In HSCT the ultimate aim is to successfully replace the hematopoietic system of the 
recipient with a donor-derived hematopoietic system. However, in some cases the recipient 
hematopoietic system endures, most commonly after a RIC regimen. In those cases, the 
term mixed chimerism (MC) is often used. In general, MC is defined as having in between 
5-95% recipient-derived hematopoietic cells remaining after HSCT. 
 
The term chimerism comes from the mythical beast Chimera from Greek mythology. The 
beast was a hybrid made up of several parts of different animals, though most often 
portrayed as a lion with the head of a goat and a snake for a tail. As patients with MC have 
an immune system that is derived both from the donor and the patient, the term mixed 
chimerism was coined. One of the first extensive studies describing MC post-HSCT was 
done by Ildstad et al in 1985, where they transplanted mice with a mixture of donor- and 
patient-derived hematopoietic stem cells. These transplanted mice were better able to 
tolerate skin grafts than those who only received donor-derived hematopoietic cells.169 The 
first reports on mixed red cell chimerism in humans post-HSCT were published in the late 
1980s.170, 171 Since then the field has progressed and MC has also been observed in other 
cellular subsets.  
 
To determine whether a patient has MC or full donor chimerism (DC) post-HSCT, the 
percentage of recipient- and donor-derived cells is assessed. Several techniques have been 
used for this and currently most are polymerase chain reaction (PCR)-based. In essence, 
samples from patient blood and BM are assessed for the frequency of recipient and donor-
specific DNA motifs in cell subsets.172 In our centre, myeloid, T, B and occasionally NK 
cells are assessed. Moreover, in general, cells from blood and from the BM are assessed 
separately.  
 
Frequencies of recipient cells may also vary dramatically between cell subsets or between 
blood or BM samples. For instance, it is possible for a patient to be mixed in blood but not 
in BM, or only have donor T cells, yet have some remaining recipient NK cells. However, 
in general, chimerism frequency in cellular subsets tend to be quite similar.173, 174  
 
The phenomenon of MC has also caught the attention of clinicians in the solid organ 
transplantation field, especially after the studies performed by Ildstad et al in 1985. 
Researchers in this field have toyed with the idea of creating a temporary mixed chimeric 
hematopoietic system in the patient before solid organ transplantation.175-177 The patient 
would receive hematopoietic cells from the donor around the time of solid organ 
transplantation. If a MC situation is established, a large part of the patient's immune system 
would recognize the transplanted solid organ as self and would teach the other part of the 
immune system to ignore the non-self signal from the transplanted organ. This is the 
previously mentioned process of peripheral tolerance. After a couple of weeks or months 
the donor-derived immune cells would be rejected since the patient was not preconditioned, 
but hopefully by that time they will have educated the patient’s immune cells to tolerate the 
new organ. The patient would then theoretically no longer need immunosuppressant drugs 
to protect the organ from rejection. In a solid organ transplantation, patients currently need 
to take lifelong immunosuppressant drugs, which severely increases their risk of infections 
and secondary malignancies. This chimerism model for solid organ transplantation would 
most likely only be feasible for live organ transplants, e.g. liver and kidney transplants, as 
the patient would need sufficient hematopoietic cells from the same donor around the day 
of organ transplantation. This is often not possible in cadaveric organ transplants, such as 
heart or lung. Though not used in human subjects extensively as of yet, experiments have 
so far yielded interesting and promising results.178-181  
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While MC is seen as a potentially beneficial phenomenon in solid organ transplantation, in 
HSCT it is often perceived as something potentially dangerous.182, 183 As mentioned before, 
if a MC develops in patients with malignant disorders, threatening relapse is often 
suspected. DLIs and modulation of the immunosuppressive treatment are often given in 
those cases to boost the donor hematopoietic stem cells to counteract relapse or donor graft 
rejection.184-186  
 
However, in some cases, especially in non-malignant disorders, presence of residual 
recipient cells does not automatically indicate graft rejection or disease relapse. There have 
been several reports where long-term stable MC has been reported post-HSCT without any 
serious adverse effects. Moreover, in some instances it seems that the patients with MC are 
doing equally well or even better than their DC counterparts. These cases have been seen in 
limited cohorts only, often, though not exclusively, in siblings transplanted for non-
malignant disorders.80, 187-191 
 
In most cases, MC is a phenomenon that occurs shortly post-HSCT and gradually 
disappears after about a year. This is partly due to the general engraftment process of the 
donor-derived hematopoietic system and/or DLIs. In rare cases, MC persists, and is referred 
to as long-term stable MC. These instances have been the focal point of two of the four 
papers presented in this thesis (Paper III and IV). In these patients, MC is still present after 
more than 5 years post-HSCT. Frequency of remaining recipient cells varies largely 
between patients. Some present with just 5-10% recipient-derived cells, while some may 
have up to 90% recipient-derived cells. In the latter case, most of the patients are 
asymptomatic and are disease free with just a 10% fully functional donor-derived 
hematopoietic system.  
 
Long-term stable MC is a fairly rare phenomenon, it only arises in a small fraction of 
patients and as such it is an understudied occurrence. For instance, it is unclear whether 
remaining recipient cells remain functional or if they are mostly anergic. And if they are 
functional, it is unclear whether they fulfil special niches in the immune system or whether 
they function as a redundant system of the donor-derived system. Moreover, why do some 
patients develop MC and others do not? These are just some of the mysteries that 
encompass MC development. 
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2 AIMS 
The aims of this thesis were to increase knowledge on the co-existence of donor- and 
recipient-derived cells post-HSCT. As it is impossible to perform research on all aspects of 
this within a PhD project, or arguably even within a person’s lifetime, focus was put on 
different aspects of GVHD and MC. Specifically, we aimed to: 
 
1. Identify prognostic markers for aGVHD development. 
 
2. Identify diagnostic markers in blood for cGVHD diagnosis. 
 
3. Gain insights into the pathophysiology of cGVHD. 
 
4. Gain insights into the mechanism behind long-term stable MC in non-malignant 
patients. 
 
Aim 1 is discussed in Paper I, aim 2 and 3 in Paper II, and aim 4 in Paper III and IV. 
  
 32 
 
 
  33 
3 METHODS 
This section will very briefly explain the general idea behind the methods used in the 
research for this thesis. For a detailed protocol explaining the steps and reagents used, I 
would like to refer to the attached papers and the references therein.  
 
3.1 ETHICAL IMPLICATIONS 
All research performed for this thesis was approved by the Regional Ethical Review Board 
in Stockholm, Sweden, and performed according to the amended Declaration of Helsinki. 
Where required, informed consent was acquired from included patients. Patients were asked 
to donate blood samples and to fill in an in-house questionnaire (for Paper IV). 
 
3.2 ELISA 
In an enzyme-linked immunosorbent assay (ELISA), levels of a soluble factor can be 
measured by means of light intensity. The soluble factors are bound by an antibody coupled 
to an enzyme. A substrate is added which the enzyme can cleave, producing a colour 
change of the sample. The light intensity is dependent on the concentration of the soluble 
factor of interest. The measured intensity is correlated to a standard curve of known 
concentrations coupled to a known light intensity. Only one factor at a time can be analysed 
with this method. In this thesis, levels of BAFF and antibody concentrations against 
immunisation antigens were assessed by ELISA for Paper II and IV.  
 
3.3 MULTIPLEX ASSAY 
A multiplex assay also allows for the analysis of levels of soluble factors. In contrast to 
ELISA, this method uses antibody-coated beads of different sizes and can be used to 
analyse multiple factors at the same time. While this method is more complicated and 
expensive, it yields significantly more information than a single ELISA. In this thesis, 26 
different cytokines and chemokines were analysed by multiplex (Luminex) for Paper I, II 
and IV. 
 
3.4 IMMUNONEPHELOMETRY 
In an immunonephelometry assay, antibody levels are measured. Samples are sorted (in the 
case of this thesis, sorted for isotype) and left to clump together. The sample is then passed 
through a light beam. The scatter of the light is measured and compared to a standard curve. 
The standard curve is made up of known concentrations of antibody correlated to the spread 
of light they produce. Immunonephelometry was used for Paper IV.  
 
3.5 CHIMERISM ANALYSIS 
To determine if a patient is a mixed chimera or a full donor chimera, a chimerism analysis 
is used. In this analysis, the percentage of remaining recipient-derived cells are determined. 
This is performed by analysing the sample taken post-HSCT for certain DNA motifs and 
comparing them to a sample from the donor and recipient before HSCT. If the sample 
resembles the donor sample for 100%, the patient has achieved DC. However, if some 
patient motifs remain in the post-HSCT sample, we can say there is MC. Based on how 
much patient motif is detected, the percentage of remaining patient cells can be calculated. 
The DNA motifs that are analysed can be as small as single nucleotide polymorphisms 
making the technique very sensitive. It is even more so as we can use PCR to amplify the 
signal of the sample to ensure enough DNA is present for the analysis prior to sequencing. 
Chimerism analysis was done for Paper III and IV. 
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3.6 WESTERN BLOT 
Levels of intracellular proteins can be measured by western blot. While it is a relatively old 
technique, it is still used in research as it is not yet possible to perform intracellular flow 
cytometry staining for all intracellular proteins.  
In a western blot assay, protein from cells are first separated on an SDS page gel. The 
proteins migrate through the gel under the influence of an electric current. Larger proteins 
will take longer to migrate through the gel than smaller ones, thus separating proteins by 
size. When the spread of the proteins of interest is deemed to be ideal for the specific 
analysis, the current is stopped and the gel removed. The proteins are now “blotted” onto a 
nitrocellulose membrane, again under the influence of an electric current, but this time from 
the gel towards the membrane. After this process, the proteins of interest can be stained 
with protein-specific antibodies for the protein on the membrane. After staining, an enzyme 
and substrate are added which will result in a chemiluminescent signal. The intensity and 
location of the signal will indicate the specific protein and its original concentration in the 
sample. Usually, the intensity of a “housekeeping gene” is used to calculate the relative 
intensity.  
In this thesis, we analysed whole lymphocyte samples of patients for expression of LCK, 
ZAP-70, CD3d-chain and the phosphorylation of serine and tyrosine residues for Paper IV. 
 
3.7 MITOGENIC STIMULATION ASSAY 
Lymphocytes can be activated in many ways, even by some chemicals. One of these 
chemicals is phorbol 12-myristate 13-acetate (PMA). Just up to 4 hours of exposure to 
PMA at certain concentrations will start the activation of T cells and the production of 
certain cytokines. If the cells are also exposed to a chemical called Brefeldin A, these 
produced cytokines will then not be excreted but instead remain in the cell. This allows the 
production of cytokines in each individual cell to be analysed by flow cytometry. In Paper 
IV, we performed a mitogenic stimulation with PMA and Brefeldin A for 4 hours, to assess 
the ability of certain cellular subsets to produce IFNg and IL-2. 
 
3.8 MIXED LYMPHOCYTE REACTION 
In a mixed lymphocyte reaction (MLR), lymphocytes of two (or more) different individuals 
are mixed and left to react to each other. Usually, lymphocytes from one of the individuals 
is irradiated to ensure they will not proliferate. Thus, only the non-irradiated lymphocytes 
will be able to respond, become activated and proliferate during the reaction. As a negative 
control, lymphocytes from the responding individual are incubated for the same amount of 
time in the same setting but without the presence of irradiated lymphocytes of the second 
individual. The positive control on the other hand will contain lymphocytes from the first 
individual which will be co-cultured with a chemical known to activate the cells. 
Depending on the exact nature of the experiment this chemical is quite often 
phytohemagglutinin A (PHA). PHA is known to stimulate T cells in a broad sense.  
In this thesis, we used lymphocytes from a donor-derived allograft as our responding cells, 
our first individual. Lymphocytes from the corresponding patient were irradiated and thus 
used as our second individual. Donor-derived allograft and patient lymphocytes were co-
incubated in a 10:1 setting. The MLR was then left to incubate for 5 days. After 5 days, 
supernatant containing produced cytokines and chemokines were taken for analysis by 
multiplex assay. The remaining cells were harvested and stained to be analysed by flow 
cytometry. MLRs were performed for Paper I. 
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3.9 FLOW CYTOMETRY 
In flow cytometry, the presence of intracellular and extracellular markers is analysed at a 
single cell level by fluorescence detection. Cells are first stained with antibodies targeting 
specific markers. Each antibody is labelled with a different fluorochrome. These 
fluorochromes will emit light at a specific wavelength after being exited by a laser at 
another wavelength. The fluorescence intensity indicates the amount of antibody bound to 
the cell. In a special flow cytometry machine, a cell sorter, we can collect cells in a separate 
tube based on the expression of certain markers. These sorted cells can then be used for 
further analysis as a “pure” cellular population. 
Different fluorochromes overlap in wavelength, complicating flow cytometry analysis. This 
limits the number of markers one can analyse at the same time on a single cell. This number 
can be increased by carefully matching fluorochromes to certain markers and by increasing 
the number of lasers on the machine.  
In this thesis, up to 9 different markers were analysed on a single cell level. A summary of 
the markers and their function is presented in Table 3 together with the markers used for 
mass cytometry. Normal flow cytometry was performed for Paper I, II and IV, and flow 
cytometry sorting was done for Paper IV. 
 
3.10 MASS CYTOMETRY 
Mass cytometry resembles flow cytometry in many ways. In mass cytometry, the antibodies 
used to stain markers on individual cells are tagged with metal isotopes instead of 
fluorochromes. After staining, the cells are then run through a mass cytometer, a CyTOF 
(Cytometry by Time of Flight) in our study, which vaporizes the cells and then uses mass 
spectrometry to analyse each cell. The concentration of metal isotopes per cell indicates the 
expression level of each marker. As the cells are vaporized during this process, it is not 
possible to sort the cells. A benefit of mass cytometry over flow cytometry though is that in 
mass cytometry the overlap between antibodies is basically non-existent as it is not 
dependent on analysis of emission of light. Instead, a limiting factor is the availability of 
metal isotopes.  
In this thesis, we performed mass cytometry to analyse up to 33 markers on a single cell. A 
summary of the markers and their function is presented in Table 3. Mass cytometry was 
performed for Paper II. 
 
3.11 STATISTICS 
Most statistical analyses performed in the papers in this thesis were univariate non-
parametric tests. In univariate tests, groups are compared on whether they differ statistically 
significant from each other for a single parameter. The choice was made for non-parametric 
tests as normality could not be assumed for all markers in all groups. The following tests 
were performed: Mann-Whitney-U, Kruskal-Wallis, Wilcoxon signed-rank, Friedman, 
Fisher Exact, Pearson’s c2 test and Spearman’s rank correlation (Paper I, II, III and IV). 
Post-hoc analysis used either the Bonferroni correction or Dunn’s adjustment. The 
appropriate test was used depending on whether two or more groups were compared, 
whether the data was continual or categorical and whether the groups were independent or 
dependent on each other. 
Moreover, in some instances a multivariate test was performed. Examples of these are the 
logistic regression (Paper IV) and risk factor analysis (Paper I). In these tests, the groups 
are tested for several parameters at the same time.  
For most statistics the software SPSS, Statistica, R or Graphpad was used. In the case of the 
mass cytometry data, the software Citrus was used.  
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Table 3. Markers analysed by flow and mass cytometry. Some markers are also expressed by other cells than just the 
subset indicated.5 Only the cell subsets for which the markers were analysed in this thesis are mentioned. 
Marker Characteristic Cell subset 
CD3 Part of the TCR complex, used to identify T cells T  
CD4 Co-receptor associated to the TCR complex, binds HLA class II Helper T 
CD5 Attenuates TCR signalling B and T  
CD8 Co-receptor associated to the TCR complex, binds HLA class I Cytotoxic T  
CD11c Subunit of an integrin Myeloid  
CD16 Fc receptor, mediates antibody-dependent cell-mediated cytotoxicity NK 
CD19 Co-receptor associated to the BCR complex, used to identify B cells B  
CD20 Maturity marker B  
CD25 IL-2 receptor a chain Regulatory T 
CD27 Co-stimulatory receptor, part of the tumour necrosis factor receptor family B and T  
CD28 Co-stimulatory receptor T  
CD31 Adhesion molecule T 
CD38 Activation marker B and T 
CD39 Catalyses extracellular ATP, suppressive effect on immune response Regulatory T 
CD44 Adhesion marker Leukocytes 
CD45RA Marker for memory differentiation T 
CD45RO Marker for memory differentiation T 
CD56 Adhesion marker, used to identify NK cells NK 
CD57 NK cell marker B, NK and T 
CD69 Marker for early activation T 
CD94 Lectin, pairs to form a heterodimer with CD159, binds to HLA-E NK and T 
CD95 FAS receptor, marker for apoptosis induction T 
CD107a Degranulation marker  T 
CD127 IL-7 receptor T 
CD152 / CTLA-4 Negative regulator for activation T 
CD158b Inhibitory KIR receptor NK 
CD159 / NKG2a Inhibitory KIR receptor, pairs to form a heterodimer with CD94, binds to HLA-E NK 
CD161 Marker for MAIT cells, also regulates NK cell cytotoxicity T 
CD183 / CXCR3 CXC chemokine receptor, regulates chemotactic migration B and T 
CD185 / CXCR5 CXC chemokine receptor, regulates chemotactic migration B and T 
CD194 / CCR4 CC chemokine receptor B and T 
CD195 / CCR5 CC chemokine receptor, used by HIV to enter the cell T 
CD196 / CCR6 CC chemokine receptor, homing to the gut B and T 
CD197 / CCR7 CC chemokine receptor, marker for memory differentiation T 
CDw199 / CCR9 CC chemokine receptor, homing to the gut B and T 
CD278 / ICOS Immune checkpoint protein B and T 
CD279 / PD-1 Negative regulator for activation B and T 
FoxP3 Transcription factor for regulatory T cells Regulatory T 
Granzyme B Secreted together with perforin to induce apoptosis in target cell NK and T 
HLA-DR HLA class II receptor, upregulated during activation B and T cells 
IgD Immunoglobulin expressed by naïve mature B cells B 
IgM Immunoglobulin expressed by naïve mature B cells B 
IL-2 Pro-inflammatory cytokine, expressed and produced after activation, induces T cell proliferation T 
IFNg Pro-inflammatory cytokine, expressed and produced after activation, activates macrophages and induced Ig class switching T 
Ki-67 Proliferation marker, absent in resting cells B, NK and T 
TCRgd TCR made up by a g and a d chain T 
TCRab TCR made up by an a and a b chain, most common variant T 
TCRVa7.2 TCRab containing an a7.2 chain, marker for MAIT cells T 
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4 RESULTS & DISCUSSION 
The main focus points of this thesis revolve around increasing knowledge on the co-
existence of donor and recipient post-HSCT. After the conditioning regimen, the HSCT is 
performed as an infusion of the allograft, i.e., the donor’s hematopoietic cells. The graft 
needs to “settle in” and “learn” to co-exist in its new environment, i.e., the host or recipient. 
This complicated process of learning to adapt to the new situation and some of the 
difficulties patients may encounter during this process are discussed in the introduction. 
Several complications may arise, some of which can be life threatening. Fortunately, in 
most cases the patient survives with a good quality of life. The patients with a complicated 
HSCT course are those that could benefit from further understanding the mechanisms 
behind these complications. Better knowledge will result in faster interventions or new 
therapy strategies.  
 
The magnitude of potential complications in HSCT cannot all be investigated within an 
individual PhD programme, therefore this thesis focused on aspects of aGVHD (Paper I), 
cGVHD (Paper II) and long-term stable MC (Paper III and IV). All three topics revolve 
around the interplay between the donor graft and recipient cells. In the first two topics, the 
allograft and recipient cells do not co-exist peacefully, as the graft attacks the recipient 
tissue. In the last topic, a tolerance between the graft and recipient has developed; they 
seem to co-exist in peace. However, what makes the well-functioning co-existence so 
special is that there is not just a tolerance from the graft towards the recipient tissue, there is 
also a tolerance from the recipient towards the graft.  
 
For the sake of simplicity, the research will not be discussed in chronological order of when 
it was performed and published, instead, it will be discussed in the order of how a patient 
undergoing HSCT may encounter them. First, the results from Paper I on aGVHD will be 
discussed, followed by Paper II on cGVHD and finally, Paper III and IV which focused 
on long-term stable MC. 
 
 
 
4.1 CO-EXISTENCE OR WAR? 
 
4.1.1 Predicting Acute GVHD 
As previously discussed, aGVHD is a common complication of HSCT. Low aGVHD 
grades are often treatable and can, in malignant disorders, be interpreted as beneficial. They 
indicate a strong allo-response which is required for an effective GVT effect. However, 
severe grades of aGVHD also occur. These higher grades are considerably more difficult to 
treat and are associated with high morbidity and mortality rates. 
 
While some risk factors are known for aGVHD, it is still hard to accurately predict whether 
a patient has an increased risk for aGVHD at time of transplant. Some described risk factors 
are: HLA mismatch between donor and recipient, older patient and donor age, grafts from 
female donors given to male patients, the use of PBSCs, unrelated donors and ATG.192-198 
That said, there is some disparity in which risk factors may play a more determining role in 
aGVHD development than others. This could partly be explained by the difference in 
HSCT protocols and the heterogeneity of patient cohorts between centres. 
 
Due to all of this, there is a need for more reliable and consistent risk factors or biomarkers 
for aGVHD development. Both predictive and diagnostic biomarkers are of interest. Similar 
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to risk factors, only a few biomarkers have been identified, most of which are soluble 
markers. A nice review was recently published by Ali et al which illustrates how this field 
has slowly grown over the last two decades.199 
 
In an early example of a diagnostic biomarker study, four proteins (IL-2Ra, tumour 
necrosis factor receptor-1 (TNFR1), IL-8, and hepatocyte growth factor) were identified to 
be diagnostic for acute GVHD.200 A follow-up study by the same group identified REG-3a 
levels to be diagnostic of GI tract GVHD.201 Other studies discovered a role for certain 
microRNAs202 and ST2203 for aGVHD onset and therapy resistance, respectively. New 
methods like mass-spectrometry are being utilized to identify diagnostic markers, for 
instance, by analysing serum protein patterns to stratify patients with or without aGVHD.204 
 
While diagnostic biomarkers are valuable to understand aGVHD development and 
progression, aGVHD diagnosis is well established by the Glucksberg criteria.136, 137 The 
guidelines make use of relatively non-invasive methods (bilirubin levels, volume of 
diarrhoea and percentage of skin lesions) to assess aGVHD grades (Table 1). Since, severe 
grades of aGVHD can be difficult to treat, in an ideal world we could prevent patients from 
even progressing to grade II-IV aGVHD. To prevent aGVHD, we first need to accurately 
predict it. As such, there has been more emphasis on finding predictive markers rather than 
diagnostic markers in the last years. 
 
Hence, studies have focused on finding ways to predict patients at higher risk to develop 
severe grades of aGVHD. An example is a study where levels of TIM-3, a marker for T cell 
exhaustion, was predictive of severe aGVHD.205 This was corroborated by a later study 
where TIM3, IL-6 and sTNFR1 were found to be predictive of grade III-IV aGVHD 
development. TIM3 levels could predict aGVHD as soon as 14 days post-HSCT.206 
Another early predictor of aGVHD was found in patients transplanted with cord blood, ST2 
was predictive of grade II-IV aGVHD at day 28.207 Some studies have attempted to 
combine different prognostic markers to create algorithms that can predict risk for aGVHD. 
For instance, one study combined the previously mentioned diagnostic markers REG-3a, 
TNFR1, IL-2Ra and ST2, to stratify patients into low-risk and high-risk groups for onset of 
severe acute GVHD and therapy response. The combination of REG-3a and ST2 yielded 
the best results.208, 209  
 
While soluble markers to predict aGVHD have received a lot of attention, probably due to 
their ease of use in a clinical setting, some studies have aimed to identify cellular markers. 
For instance, at day 30 post-HSCT, low levels of granzyme B positive Tregs was predictive 
for aGVHD development.210 Invariant NKT cells have also been suggested as a potential 
biomarker to predict aGVHD. A reduced expansion ability of donor iNKT cells, low iNKT 
cell dose in grafts and a low iNKT/T cell recovery ratio post-HSCT were all positively 
correlated to increased grades of aGVHD.211-213 Similar to the approach with soluble 
markers, another study created a five-parameter biomarker score. They combined 4 cellular 
subsets (CD4+ T cells, CD8+ T cells, CD4/CD8 ratio, CD19-CD21+ precursor B cells) 
with one soluble marker (sIL-2R) to predict aGVHD and/or overlap syndrome.214  
 
Biomarker source is important. The studies described so far, all focused on identifying 
markers in patient material. Though more limited, some studies have also focused on 
identifying markers in the donor-derived grafts. For instance, two studies performed in our 
group identified grafts of superior viability and those containing lower frequencies of naïve 
CD8+ T cells to be linked to a reduced risk of aGVHD.215, 216 One meta-analysis of 14 
studies concluded that a high frequency of regulatory T cells correlated to lower non-
relapse mortality and a reduced risk of aGVHD.217 Another recent study identified a 
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correlation of high effector T cell frequencies and aGVHD. They also identified a 
protective function of high frequencies of graft CD34+ cells against aGVHD.218 This was 
corroborated in a later study where patients receiving CD34+ selected grafts had a lower 
grade II-IV aGVHD incidence.219 Finally, a third study from our group, and the pilot study 
for Paper I, identified, among other subsets, that reduced frequencies of gd T cells were 
linked to grade II-IV aGVHD development.220  
 
While a few potential biomarkers, both predictive and diagnostic, have been identified and 
are being studied in detail, there is still no clear-cut biomarker that can easily predict 
aGVHD. Moreover, useful biomarkers in one centre may not be the same in another, due to 
the differences in HSCT protocols. Therefore, our aim for Paper I was to identify 
diagnostic markers for aGVHD development that could be utilized in our clinical setting. 
Hence, the methods had to be simple and easy to implement in a routine laboratory.  
  
Paper I focused on elucidating predictive biomarkers for aGVHD, with a focus on cellular 
markers. We analysed grafts from more than 100 donors and correlated them to primary 
aGVHD outcome in the corresponding grafted patients. Development of aGVHD after DLI 
infusion was not taken into account in aGVHD grading and grouping the results.  
 
Patients were split into two groups, one group that developed either no aGVHD or grade I 
aGVHD against a group of patients with grade II or higher aGVHD. This stratification was 
based on clinical relevance. While it would have been interesting to analyse patients with 
higher grades separately, unfortunately, such an analysis was not feasible due to the limited 
number of patients with grade III-IV aGVHD.  
 
There were no differences observed in clinical parameters between the grade 0-I and grade 
II-III aGVHD patient groups. All grafts were extensively assessed by flow cytometry and 
the immune phenotypes of the two patient groups were compared. Several cellular subsets 
of interest emerged. Of particular interest were the reduced frequencies of CD4+, CD27+, 
CD28+ and CD127+ T cell subsets and the increased frequencies of CD8+ and 
programmed cell death 1 (PD-1)+ T cell subsets in the patient group with grade II-III 
aGVHD.  
 
While patients with grade II-III aGVHD received grafts with a more pronounced shift 
towards CD8+ T cells than patients with grade 0-I aGVHD, all grafts contained more 
CD8+T cells than CD4+ T cells. The normal distribution of blood T cells is the opposite, 
with more CD4+ T cells than CD8+ T cells. The inverted CD4/CD8 ratio is a common 
feature post-HSCT.221-223 However, this inverted ratio is seemingly already present in the 
grafts, indicating that this is not purely a result of the reconstitution. The shift in CD4/CD8 
ratio was seen in both BM and PBSC grafts, so it seems unlikely that the stem cell 
extraction itself accounts for this shift. Perhaps the graft processing before transplant 
favours survival of CD8+ T cells over CD4+ T cells. Data on immune phenotyped grafts at 
different time points from collection to infusion has not been published to our knowledge. 
Hence, it would be interesting to determine whether graft procurement and handling affects 
the cellular immune phenotype and the impact that may have on the transplant outcome.  
 
As mentioned, T cells positive for CD28 or CD127 were found at lower frequencies in 
grafts given to patients who later developed grade II or higher aGVHD. Both markers are 
involved in T cell activation. CD28 is the costimulatory signal required for primary 
activation of a T cell and CD127, the IL-7 receptor-a chain, is central in T cell 
proliferation. From the reduced expression of CD28 and CD127 we can thus speculate that 
the grafts given to grade II-III aGVHD patients were of a more naïve memory phenotype. 
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This finding is in line with several other studies where a positive correlation existed 
between naïve memory T cells and aGVHD.216, 224-226 
 
However, lower CD127 expression could also be interpreted as a shift from naïve to 
effector memory phenotype of the grafts. After activation, CD127 is downregulated upon 
maturation as effector memory T cells express hardly any CD127. Additionally, since 
effector memory T cells no longer need co-stimulation, this would fit the reduced CD28 
expression as well. It would also fit the observed increased expression of PD-1. While PD-1 
is mostly seen as an exhaustion marker, it is constitutively upregulated on activated cells as 
a negative feedback mechanism.227 Moreover, the reduced expression of CD28 and 
increased expression of PD-1 nicely complement each other. These markers are known to 
have mostly opposite functions in the costimulatory/inhibitory aspect of the T cell 
activation cascade.228  
 
When analysing the grafts for memory phenotype (by CD45RO and CCR7 expression) 
there were no statistically significant differences between the memory subsets of the patient 
groups. However, we did identify a trend for a shift from naïve towards a more effector 
memory phenotype in the grafts given to the grade II-III aGVHD patient group. 
 
It is interesting to consider the effect of administering grafts with a more pronounced 
effector memory phenotype. Effector memory T cells do not require co-stimulation and can 
thus be triggered to react and destroy simply by receiving distress signals from the tissue. 
However, preventing co-stimulation by blocking CD28, seems to still be able to impair and 
delay effector memory T cell response to a second infection to some extent. The exact 
mechanisms are not entirely clear yet and, as such, this is still somewhat controversial.229, 
230 Nevertheless, as HSCT patients experience extensive tissue damage due to the 
conditioning regimen, there will be plenty of danger and warning signals for the effector 
memory T cells to react to. Add to this that the donor cells will detect the recipient tissue 
cells as non-self, since all patients have some degree of mismatch in either the major or 
minor histocompatibility antigens, and you have a recipe for immunologic disaster.  
 
Even though the results of the cellular subsets found in Paper I are interesting on their 
own, it would be even more interesting if these markers had some actual predictive value. 
Hence, we performed a risk factor analysis and created a receiver operating characteristic 
(ROC) curve (Figure 11). The risk factor analysis may be easier to comprehend but it only 
looks at the data in a binary manner. An ROC curve calculates for each possible threshold 
the true positive rate versus the false positive rate and visualizes them on a graph in the 
form of a curve. The more the curve hugs the upper left corner, the better the combination 
of markers is at accurately predicting the binary outcome, development of aGVHD in this 
case. An ROC curve will also give an area under the curve (AUC) value for each model 
tested. This allows for the selection of the best model by comparing AUC levels.  
 
We started with the risk factor analysis to assess whether the above-mentioned subsets 
would equally contribute to the risk of grade II or higher aGVHD. As CD4 and CD8 
expression are related, we chose to include only one of these markers. The choice was made 
for CD4 expression, based on the higher availability of CD4 fluorescence markers and the 
simplicity of gating CD4 over CD8.  
 
Patients were assessed to have a risk factor for each marker if the grafts presented below 
median frequencies of CD4, CD27, CD127 and CD28 expressing T cells and an above 
median frequency of PD-1 gated T cells. Hence, the patients were divided in different 
groups depending on the amount of risk factors.  
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The combined effect of all five risk 
factors led to a grade II-III aGVHD 
incidence of 76%, while having four 
risk factors or less led to an incidence 
of between 19-37%. We then aimed to 
identify which risk factors had the most 
pronounced effect on the grade II-III 
aGVHD incidence. The combination of 
the risk factors PD-1 and CD127 had an 
incidence of 67%, which, besides 
including all five risk factors, led to the 
highest incidence prediction. These two 
markers had the greatest power to 
predict aGVHD.  
 
An ROC curve was plotted for these 
two markers to assess the predictive 
value of the markers. The combined 
effect of PD-1 and CD127 expression 
on total T cells led to an AUC value of 
0.74, which indicates a strong 
predictive value. However, a second 
cohort will be needed to verify these 
results. If these results hold true, it 
would be particularly interesting as 
these are merely three markers (PD-1, 
CD127 and CD3) that would need to be 
analysed during graft processing. As 
most centres already assess graft 
viability by flow cytometry, adding one 
more sample should be possible. As a result, clinicians will receive information not only on 
graft viability but also an aGVHD risk assessment at the time of transplantation. This 
knowledge can positively influence patient monitoring and treatment post-HSCT. For 
instance, when early aGVHD symptoms arise, a patient at increased risk could be treated 
earlier or more intensively, while a low risk patient could be treated accordingly. 
Unnecessary treatment can thus be avoided, resulting in less infections, higher quality of 
life and reduced costs for the clinic. 
 
The six above mentioned T cell markers were not the only markers that differed between 
the grade 0-I and grade II-III aGVHD patient groups. We also identified differences in a 
MAIT subset and a B cell subset (Figure 12).  
 
As mentioned in the introduction, MAIT cells are a specialised subset of T cells usually 
found in low frequencies in the blood. They are, as the name already suggests, usually 
associated to the mucosa, and are thus more abundant in the skin, liver and gut.27, 231 As 
these tissues are also the sites where aGVHD occurs, the potential role of these cells in 
aGVHD is interesting.  
 
MAIT cells are defined as T cells that are double positive for TCRVa7.2 and CD161. 
Moreover, most MAIT cells do not express CD4. As a mucosal-associated cell, most MAIT 
cells express a variety of homing receptors for varying mucosal tissues. Classic examples of 
these are CCR6 and CCR9.27, 28, 232  
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Figure 11. A Risk Factor analysis and ROC curve of the 
impact of PD-1 and CD127 on aGVHD development. 
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The MAIT subset that differed between the 
two patient groups was a CCR9+ CD4- 
CD8+ MAIT cell. This subset was found 
in lower frequencies in grafts given to 
patients with grade II-III aGVHD (Figure 
12A). Since patients who did not develop 
high grades of aGVHD received higher 
frequencies of this MAIT cell subset, we 
can hypothesise that this subset might have 
a protective role in aGVHD development. 
Perhaps these cells can dampen the 
immune response in some way. For 
instance, by clearing up the damage 
associated to the tissue, negating the 
distress signal sent out by the tissue to the 
innate and adaptive immune mechanisms. 
 
A specific B cell subset also differed in 
frequency between the two patient groups. 
The vast majority of human B cells 
express the cellular marker CD20 (also 
known as B-1), only pro-B cells and plasma cell do not.233-235 These two cellular subsets 
respectively represent the beginning and the end phase in B cell maturation. Both subsets 
also reside in the BM. Coincidentally, the drug rituximab, often used to treat CLL, targets 
CD20 on B cells, resulting in the death of all CD20+ B cells.236, 237 
 
In this study, CD20- B cells were found at lower frequencies in the graft in the grade II-III 
aGVHD patient group (Figure 12B). These CD20- B cells are not those that are activated 
by CD4+ T cells, since these still need to mature or are producing antibodies against 
previously encountered pathogen. We could speculate that lower frequencies of these cells 
could protect the patient against CD4+ T cell driven inflammation. 
 
Due to restrictions in the flow cytometric antibody panel, we could not assess whether these 
CD20- B cells constituted pro-B cells or plasma cells. Since both cell subsets reside in the 
BM and since we have a mixed patient cohort of BM and PBSC-derived grafts, we 
analysed whether this difference in CD20- B cell frequency was not caused by a difference 
in graft source. As expected, irrespective of aGVHD development, CD20- B cells were 
more abundant in the BM grafts than in the PBSC grafts (p<.001). To assess the potential 
impact of this finding we analysed whether the CD20- B cell frequency differed between 
the aGVHD patient groups for each graft source separately. Interestingly, CD20- B cell 
frequency did not differ between the aGVHD patient groups in the BM grafts, but did differ 
in the PBSC grafts (p<.001). Hence, the CD20- B cell frequency difference observed in 
Figure 12B between the aGVHD patient groups was due to a difference in CD20- B cell 
frequency in the PBSC grafts.  
 
The CD20- B cell frequencies are low, especially in the PBSC grafts, and may not have a 
practical application in the clinic for predictive purposes. However, they may be important 
to understand aGVHD development. Identifying whether these CD20- B cells are pro-B 
cells or plasma cells could be imperative. For instance, pro-B cells will mature and 
proliferate further in the patient and may thus have a larger effect than we can perceive at 
the moment.  
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Investigations into the effect of graft source stimulated us to look into whether the graft 
source could influence the previously mentioned markers. PBSC grafts have been G-CSF 
stimulated, which may affect the activation phenotype of the immune subsets. Hence, we 
performed a similar analysis for the six markers (CD4, CD8, CD27, CD28, CD127 and PD-
1) to assess the distribution of these subsets over the graft source regardless of aGVHD 
grading. No differences between the graft source groups for subset frequencies could be 
observed. Hence, the differences we saw in marker subsets between the patient groups are 
true differences observed in the donor-derived graft and not due to the G-CSF stimulation.  
 
In addition to immune phenotyping the donor grafts, we also assessed the graft 
functionality and reactivity between the grade 0-I and grade II-III aGVHD patient groups. 
To achieve this, we performed MLRs by incubating donor graft-derived cells in three 
different settings. For the first setting (negative control), we left donor graft cells un-
stimulated in complete medium. This would illustrate baseline activity. In the second 
setting (positive control), we stimulated donor graft cells with PHA. PHA activates all 
lymphocytes, though the exact mechanism is not completely understood.238 This illustrates 
the maximum activity possible for the donor graft cells and functions as a quality check of 
the graft. Finally, the third setting was created to try and mimic the in vivo setting in the 
patients in aGVHD development. Patient lymphocytes were irradiated to ensure they would 
not proliferate and survive the incubation. Moreover, the irradiation damages the cells 
similar to the damage made by the conditioning regimen. The patient lymphocytes were 
then added in a 1:10 ratio to the donor graft cells. Hence, we seeded 10× more donor graft 
cells than patient lymphocytes.  
 
The method has some drawbacks. First off, in an MLR we test the reactivity of graft cells 
against patient lymphocytes. This is in contrast to aGVHD which is usually directed at 
epithelial cells, not lymphocytes. However, as it is not feasible to acquire skin, gut and/or 
liver biopsies of all patients, especially before HSCT, an MLR is an accepted method to 
model donor-patient reactivity in an in vitro setting.239-241 Additionally, in a patient, ratios 
of patient and donor cells are actually reversed. There are vastly more patient epithelial 
cells than donor cells post-HSCT. Therefore, perhaps it would have been truer to reality to 
seed donor and patient cells in a 1:1 ratio. Adding even more patient cells could blur the 
results at the end of the incubation as all patient cells will die due to the irradiation. Patients 
undergoing HSCT are usually not in the best of shape and have undergone other therapies 
prior to becoming eligible for HSCT. As a result, these patients are usually lymphopenic. 
We tried to acquire as much lymphocytes as possible using blood samples taken before the 
start of conditioning regimen. We feel that the 1:10 ratio used, although not ideal, was the 
best option under the circumstances. Performing MLRs are thus not without its 
complications, but they are one of the most used in vitro aGVHD models for patient 
material.  
 
We performed an MLR for 80 patient-donor pairs. Some patients and donors were excluded 
due to low patient lymphocyte numbers or logistic issues. The MLRs were assessed by flow 
cytometry. The choice to focus on T cells was done for several reasons. One reason is the 
fact that aGVHD is described to be a T cell driven disease. Secondly, due to low patient 
lymphocyte numbers, we were limited in the number of flow cytometric panels. Lastly, 
most NK and B cells do not survive the incubation without proper addition of relevant 
cytokines, nutrients or specific stimulator cells.242 
 
Analysis of blast formation, indicative of T cell activation, in the three different settings 
after the MLR, demonstrated that the donor graft cells in the PHA setting were extensively 
activated while the unstimulated and 1:10 settings resembled each other with few blasts. 
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Moreover, frequencies of some of the main cellular subsets of the immune system, total T 
cell, CD4+ T cell, CD8+ T cell, regulatory T cell and maturation status, were similar 
between the patient groups for all three MLR settings. Looking slightly more in depth to 
several cellular subsets did yield some differences between the grade 0-I and II-III aGVHD 
patient groups for the 1:10 and PHA setting. As the 1:10 setting is deemed to be the in vitro 
model for aGVHD development, we will focus the discussion of cellular subsets based on 
this setting. 
 
In the 1:10 setting, there were several interesting statistical differences in CD4+ T cell 
subsets between the grade 0-I and II-III aGVHD patient groups. CD4+ T cells positive for 
activation markers CD94, CD56 and CD69 and positive for degranulation marker CD107a, 
were found at increased frequencies in grafts given to patients who later developed grade 
II-III aGVHD. Frequencies of CD4+ T cells positive for exhaustion markers PD-1 and 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) were also increased in these 
patients. This indicates a more recently activated cytotoxic phenotype in those grafts after 
being exposed to recipient lymphocytes. It is possible that the grafts given to these patients 
had a lower activation threshold towards recipient antigens. This phenotype was not found 
to be statistically different in the CD8+ T cells. We can hypothesise that CD4+ and CD8+ T 
cells have differing activation kinetics243 and, as such, by looking at only a single time point 
we may have missed the optimum for (one of) these subsets.  
 
Due to patient sample availability, we were limited to assess the immune cell phenotype at 
one time point. In a future study, it would be beneficial if the MLRs could be analysed at 
several time points. This would either require larger patient samples, which will be a 
challenge as these patients already give blood for a range of clinical tests, or we would need 
to reduce the number of flow cytometric panels. If we can reduce the number of panels by a 
factor of five, we could analyse the immune phenotype on a daily basis, instead of just once 
at the end of the 5 day incubation. Perhaps this would allow us to better assess the kinetics 
of recipient antigen activation. 
 
We also collected supernatant at the end of the 5 day MLR. We hypothesised that even if 
this time point was not optimal to detect a maximum response, we would still observe 
activation in the form of accumulated soluble markers in the supernatant. Hence, we 
analysed the supernatant for 26 cytokines and chemokines. Strikingly, the only cytokine to 
truly emerge was tumour necrosis factor (TNF)a (Figure 13A). It was found at increased 
levels in the supernatant of MLRs from grafts given to patients who later developed grade 
II-III aGVHD. This was only observed in the unstimulated setting. We speculated that this 
TNFa level increase may be seen as a baseline activity in the donor-derived graft cells. 
Unfortunately, we were unable to assess cytokine levels in the actual original graft samples 
as these were treated slightly different and given to us in varying concentrations. 
Additionally, to standardise the allograft samples, we performed a density gradient 
centrifugation on all samples. Cytokines would have been washed away. Given the 
circumstances, the cytokine levels in the unstimulated settings of the MLRs are thus the 
best substitute we have for baseline cytokine activation of the graft samples.  
 
The increased TNFa levels in the unstimulated setting intrigued us, so we next assessed the 
TNFa levels in the patients before and after HSCT. First, we analysed how each patient 
group varied in TNFa levels over time. For both patient groups, we saw a marked decrease 
in TNFa between before conditioning and day 14, and a marked increase in TNFa between 
day 14 and 1 month post-HSCT. The overall pattern of TNFa levels was the same between 
the patient groups (Figure 13B). However, when we analysed TNFa levels between the 
patient groups per time point, we observed a significant increase in TNFa levels in patients 
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who later developed grade II-III aGVHD 
before conditioning and at day 0. At day 
14 and 1 month post-HSCT, differences 
in TNFa levels between the patient 
groups disappeared (Figure 13C). As a 
general and early-induced inflammatory 
cytokine, increased levels of TNFa as an 
indicator of increased risk of grade II-III 
aGVHD is to be expected. TNFa 
production has also been shown to be 
associated to complications post-HSCT 
such as severe aGVHD and interstitial 
pneumonitis.244-247 Moreover, a study in 
mice indicated a specific role for the 
soluble form of TNFa over the 
membrane bound form in GVHD 
development. By blocking the ability of 
murine donor T cells to form soluble 
TNF, mice developed less GVHD but 
retained the GVT effect.248 However, 
these associations are on their own not 
strong enough to act as a reliable 
predictive marker in the clinic.  
 
We hypothesise that TNFa in the patient 
alone is insufficient to predict aGVHD, 
however, combining TNFa levels in the 
graft and recipient may be more reliable. 
In this study, patients who developed 
grade II-III aGVHD not only had 
elevated peripheral blood TNFa levels before conditioning and at the time of HSCT, they 
also received grafts with a potential increased baseline TNFa production. This combination 
may be an important catalyst of aGVHD development. We theorise that grafts with a 
potential increased TNFa production have a low activation threshold. These cells are then 
infused into a host milieu with even more elevated levels of TNFa. Subsequently these 
cells now come into contact with a recipient epithelial cell, expressing unfamiliar 
histocompatibility antigens and a lot of costimulatory molecules, resulting in them 
delivering the immunologic attack, i.e., GVHD. This hypothesis needs further investigation.  
 
To conclude, while it is difficult to find predictive biomarkers in the diverse patient 
population undergoing HSCT, there are some cellular markers that may fulfil such a 
function. As we demonstrated, PD-1 and CD127 expression on T cells may have a 
predictive value for severe aGVHD. It should be possible to implement staining and 
analysis for these cellular subsets in clinical routine. Additionally, analyses of TNFa levels 
in the grafts and patient peripheral blood should also be possible to do in a routine manner. 
Only then, after a prospective trial in a large cohort can we truly ascertain whether these 
biomarkers hold merit as predictors of aGVHD.  
 
We feel that while the results obtained in this study are promising, there are a number of 
additional steps required to further elucidate and confirm these findings. We will discuss 
some of these in the “concluding remarks and future aspects” section.   
A B
0-I II-I
II
1
10
100
TN
F
 (p
g/
m
L)
p=.009
NON
before day 0 day 14 1 month
0
5
10
15
20
25
TN
F
 (p
g/
m
L)
0-I II-III
p=.008 p<.001
p=.003 p<.001
p=.003
C
0-I II-I
II 0-I II-I
II 0-I II-I
II 0-I II-I
II
0
10
20
30
40
50
50
100
150
200
TN
F
 (p
g/
m
L)
day 0 day 14before
conditioning
p=.034 p=.048
1 month
Figure 13. TNFa levels in patients (A) after a 5 day 
unstimulated incubation, (B-C) before conditioning, at 
day 1, 14 and 1 month post-HSCT. 
 46 
4.1.2 Quest for Biomarkers Chronic GVHD 
While aGVHD is an important and debilitating complication, cGVHD is equally important 
from a patient’s perspective. They may suffer from cGVHD for many years having an 
enormous impact on quality of life. The pathophysiology of cGVHD is less well understood 
than of aGVHD, as also discussed in the introduction. Additionally, diagnosis of cGVHD 
can be difficult and often requires biopsies. Depending on the organ affected, biopsies may 
be painful and/or dangerous. Hence, we aimed to identify potential diagnostic cGVHD 
markers in peripheral blood and potentially gain some insights into the pathophysiology.  
 
Several studies have tried to identify risk factors for cGVHD development. Several risk 
factors have been known to be overlapping with aGVHD. For instance, HLA disparity, 
older patient age, grafts from female donors given to male patients, the use of PBSCs and 
ATG. Some other described risk factors are; prior aGVHD, splenectomy and CMV 
seropositivity.192, 196-198, 249-252  
 
In the last decade, more research has focused on identifying diagnostic and predictive 
biomarkers. As cGVHD can still be difficult to diagnose correctly, especially without 
performing biopsies, I focused on diagnostic biomarkers in Paper II. 
 
Similar to aGVHD, most published data on cGVHD concerns soluble markers in peripheral 
blood of patients due to accessibility. Several studies identified BAFF levels to be increased 
in patients with cGVHD.161, 253-255 Two of these studies also observed increased levels of 
sIL-2Ra and soluble CD13 to be linked to cGVHD.253, 254 Related to BAFF, increased 
levels of a proliferation-inducing ligand (APRIL), known to be important in B cell isotype 
switching, was positively correlated with severe cGVHD and increased plasmablast 
frequencies in cGVHD patients.256 Additionally, high levels of CXCL9254, 257, 258, ST2257, 
258, TNFa259 260 and soluble MICA261 were also associated to cGVHD. On the other hand, 
high levels of IL-15 correlated to a reduced risk of cGVHD.262  
 
There are studies that have focused on identifying cellular biomarkers for cGVHD. Several 
examples of promising results are the following. Some studies have shown that low NK cell 
doses in grafts can be protective of cGVHD development.263, 264 This was corroborated in a 
slightly newer study, which identified levels of total NK cells and CD152+ (also known as 
CTLA-4) T cells to be negatively correlated to cGVHD.259 Other studies identified a role 
for B cells in cGVHD. Patients with cGVHD had lower total B cell counts, but higher 
frequencies of IgD+ B cells and pre-germinal centre B cells than those without cGVHD.255 
Another study on B cells identified higher frequencies of CD38hi plasmablasts in patients 
with ongoing cGVHD.265 In line with his finding, one study observed reduced frequencies 
of Tfh cells, though they were more activated and skewed towards an Th2 and Th17 
phenotype in cGVHD patients. This, coupled with an increased level of CXCL13, led the 
authors to speculate that the Tfh cells migrated toward the secondary lymphoid organs to 
activate and mature B cells, increasing the cGVHD severity.266 Another study identified a 
correlation between low levels of monocytes and high levels of CD34+ cells in the graft 
with cGVHD development.218 However, a more recent study observed a low incidence of 
cGVHD with patients receiving CD34+ selected grafts.219 Lastly, Th17 cells have also been 
a target of research in cGVHD. A higher frequency of Th17 cells was seen in patients with 
active cGVHD.165 Since then, Th17 involvement in cGVHD has been studied in more 
detail. A recent study focused on how Th17 frequencies in the liver affects cGVHD. They 
observed an increased infiltration of Th17 in the liver of patients with hepatic cGVHD.166 
Th17 cells are especially interesting as they have been linked to diseases such as systemic 
sclerosis267, 268, which is characterized by extensive tissue fibrosis somewhat resembling the 
fibrosis observed in cGVHD. 
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Despite all these studies, few biomarkers have made their entrance into the clinical setting 
and are currently used to diagnose cGVHD severity. Hence, we aimed to identify markers 
that could potentially be used as diagnostic tools or could help us understand cGVHD 
pathophysiology better in our patients. 
 
For Paper II we started by collecting samples from patients suffering from varying grades 
of cGVHD; mild, moderate and severe (Table 2). All patients were retrospectively 
scrutinised for cGVHD grade by studying the medical records around the time of blood 
donation. Since the NIH guidelines to score cGVHD were implemented as recently as 2014, 
we wanted to make sure all patients were classified in the same manner. As a control group, 
we collected samples from patients who did not suffer from cGVHD. All patients were at 
least 1 year post-HSCT and none were suspected of overlap syndrome.  
 
To ensure that we would not burden these patients unnecessarily, patients were asked to 
participate in the study during a routine check-up. As we collected samples from the 
patients, we identified a considerable imbalance in intake of immunosuppressive drugs 
between the different patient groups. Patients without cGVHD or mild cGVHD had not 
received long-term systemic immunosuppressive treatments, while patients with moderate 
and severe cGVHD had.  
As immunosuppressive drugs alter the immune-phenotype, the decision was made to only 
compare patients without cGVHD to mild cGVHD patients and moderate to severe cGVHD 
patients for analyses done on blood samples taken at inclusion time. For parameters around 
the day of HSCT, we compared the four patient groups to each other as at that time point 
they were still similar. 
 
In total, 68 patients were included, divided over two study cohorts. The detailed patient 
characteristics can be found in the tables of Paper II. The four patient groups were similar 
for most clinical characteristics apart from anti-T cell antibody treatment. However, this 
difference was only seen when comparing patients without cGVHD and mild cGVHD 
versus patients with moderate or severe cGVHD. There was no difference when comparing 
patients without cGVHD to mild cGVHD and when comparing patients with moderate to 
severe cGVHD. As we compared patients only in this latter manner for the rest of the 
paper, we felt the difference in anti-T cell antibody treatment, though interesting, was not a 
potential confounder for our analysis. Additionally, we found a positive correlation between 
aGVHD development and cGVHD development. This was an expected outcome, as 
aGVHD is a known risk factor for cGVHD. 
 
The patients were stratified into two cohorts. The first cohort of 53 patient samples was 
analysed by conventional flow cytometry, ELISA and a soluble marker multiplex assay. 
Moreover, 40 patients of this cohort were analysed by mass cytometry to identify novel 
cellular subsets correlated to cGVHD severity. The second patient cohort consisted of 37 
patients of whom 15 patients were new to the study and 22 had been included in the first 
cohort. The samples from the second cohort were analysed by flow cytometry to confirm 
the findings of the mass cytometry in a more routine, clinically applicable method. 
 
Ultimately, for a diagnostic marker to be successful it has to be a marker that is relatively 
easy to assess on a large and fast scale in a routine laboratory. Hence, we started by looking 
at soluble markers. We performed a 26 cytokine/chemokine multiplex assay on the patient 
plasma samples from the first cohort. Among the analysed cytokines were IL-2, IL-15 and 
TNFa, which have been linked to cGVHD severity, as discussed earlier. However, no 
differences in these cytokines or the other 23 cytokines/chemokines could be observed in 
our cohort. 
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One of the most consistent soluble 
biomarkers identified with cGVHD is 
BAFF. In our cohort, while we could 
not identify a difference in BAFF levels 
directly, we could identify a significant 
difference in BAFF/B cell ratios 
between patients without cGVHD and 
mild cGVHD and a trend toward 
significance between moderate and 
severe cGVHD patients (Figure 14). In 
line with previous studies, BAFF and 
the BAFF/B cell ratio were increased in 
patients with a higher grade of 
cGVHD. Interestingly, there were no 
differences in total B cell or memory B 
cell frequencies between the groups.  
 
It is remarkable that we could only detect a difference in BAFF levels in patients with mild 
cGVHD compared to those without cGVHD. We have hypothesised that the high dose of 
immunosuppression given to patients with moderate and severe cGVHD has had a levelling 
effect on the immune phenotype, as described in a previous paper on BAFF levels.161 In 
fact, in the other analyses we performed, most striking differences were observed between 
patients without cGVHD and patients with mild cGVHD, while differences between 
patients with moderate and severe cGVHD were often less pronounced. Though this could 
partly be due to the difficulty in grading patients as either moderate or severe, most of the 
effect is probably due to immunosuppression. 
 
Similar to the previously mentioned study161, we assessed whether it would be possible to 
analyse the impact of immunosuppression on BAFF levels within the moderate and severe 
cGVHD group. This was not possible as only one patient in this group did not receive 
systemic treatment at the time of inclusion. Therefore, we can only speculate on the effect 
of immunosuppression on the levelling of the immune phenotype between moderate and 
severe cGVHD patients. 
 
Even though it would be most practical to identify a soluble marker as diagnostic tool for 
cGVHD, we also looked at cellular phenotypes. We analysed a large variety of T, B and 
NK cell subsets by flow cytometry. No differences between the patient groups for the more 
common main cellular subsets, e.g., total T cells, CD4+ T cells, CD8+ T cells, Tregs, 
memory differentiation subsets, B or NK cells could be detected. Hence, we started to look 
in depth into rarer subsets.  
 
One of the subsets that differed between the patient categories were MAIT cells. As 
mentioned in the introduction and also the discussion section on Paper I, MAIT cells are a 
relative small cellular subset in blood. Moreover, they are a quite new discovery. Before the 
discovery of the TCRVa7.2 antibody, the closest researchers could get to MAIT cells was 
by identifying them as T cells producing IL-17 and displaying CD161 and CCR6. 
However, Th17 cells also fall under this umbrella of cells. There have been studies that 
looked at these subsets and correlated them to cGVHD, though with conflicting results. 
Both a reduced IL-17 producing T cell frequency269 and an increased Th17 cell 
frequency165 in patients with cGVHD have been observed. Hence, studies performed on 
MAIT cells before the TCRVa7.2 antibody became available are difficult to compare to 
current research. However, they do implicate Th17 or MAIT cells in cGVHD development.  
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Figure 14. Serum protein phenotype. BAFF levels and BAFF/B 
cell ratio differences between cGVHD patient groups. 
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In our study, we observed reduced frequencies of MAIT cells in patients with increasing 
cGVHD severity (Figure 15), similar to one of the aforementioned studies.269 This was true 
regardless of whether the MAIT cells were CD4-, CD4-CD8+ or CD4-CD8-. Similar to the 
BAFF results, the difference between the groups was most pronounced between patients 
without cGVHD and mild cGVHD. As MAIT cells are drawn towards the mucosal areas of 
the human body, we speculate that the MAIT cells migrate towards inflamed mucosal sites 
in patients with more severe cGVHD. While we did not perform patient biopsies to confirm 
this, studies on patients with inflammatory bowel disease and ulcerative colitis observed 
reduced MAIT cells in the blood and increased MAIT cell frequencies, or CD161 
expression, in the inflamed gut tissue.270-272 In a future study, it would be interesting to see 
if MAIT cell frequencies are indeed increased in cGVHD affected tissues.  
Interestingly, we identified a role for MAIT cells in both aGVHD and cGVHD 
development. In Paper I we observed that patients who developed higher grades of 
aGVHD received grafts with lower frequencies of MAIT cells. We hypothesised that the 
MAIT cells in the grafts might have a protective function in aGVHD development. In 
Paper II, looking at cGVHD we observed the same pattern; lower frequencies of MAIT 
cells in the blood of patients with higher cGVHD. As we assessed MAIT cell frequencies at 
the time of cGVHD, we do not know the MAIT cell frequencies in patient blood before 
cGVHD development. We can thus only use MAIT cells frequencies in cGVHD as a 
diagnostic tool and not as a predictive tool. However, it seems that for both aGVHD and 
cGVHD, receiving a graft with high MAIT cell frequency or having a high MAIT cell 
frequency in the blood is associated to a better GVHD outcome. 
 
Lastly, we observed an increased frequency of CD38+ cytotoxic T cells in patients with 
mild cGVHD compared to patients without cGVHD. No difference was observed between 
patients with moderate and severe cGVHD. Even though this finding is interesting, it is not 
entirely unexpected. CD38 expression has been linked to aGVHD development before 
(though we did not observe this in Paper I).273 While not linked to cytotoxic T cells in 
cGVHD development, CD38 has been linked to cGVHD in the context of B cells. CD38hi 
plasmablasts were linked to cGVHD in a recent study.265 We did not detect differences in 
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Figure 15. MAIT cell frequencies gated on CD4-, CD4-CD8+ and CD4-CD8- T cells. 
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CD38+ B cell frequencies in our study. However, as we did not include CD24 we could 
only look at total B cells and not specifically at plasmablasts.  
 
While the presented results are interesting, they did not identify novel subsets that may 
explain the pathophysiology of cGVHD in more detail. Hence, we decided to perform mass 
cytometry. One of the major benefits of mass cytometry is that it uses metal isotopes 
instead of fluorochromes to analyse markers on individual cells. This means that there is no 
overlap in signal, making it possible to analyse a large number of markers simultaneously 
on the same cell, potentially up to 100 markers. The only limiting factor is the availability 
of metal isotopes. This is why mass cytometry has been used more and more to immune 
phenotype individuals for various reasons. For instance, research has been done to assess 
immune variation in healthy individuals, to identify phenotype shifts in VZV infection, to 
identify rare immune cell subsets, to map the feto-maternal immune system, and to analyse 
immune phenotype after solid organ (liver) transplantation.274-278  
 
In this study, we analysed 33 markers on each individual cell. Since 33 markers result in an 
incredible large number of possible two-dimensional plots, it is not feasible to gate all 
populations manually. Hence, Citrus, an automated cell clustering software was used.279  
 
We performed mass cytometry on 40 patients. Due to sample limitations, only 40 of the 53 
patients of the first patient cohort were analysed. Several populations, or clusters of interest, 
were identified. Most differences were observed between patients without cGVHD and 
mild cGVHD and fewer differences between patients with moderate and severe cGVHD. I 
will focus on two of the six clusters identified in Paper II to differ between patients 
without cGVHD and with mild cGVHD; and on both clusters identified to be different 
between patients with moderate and severe cGVHD. An overview of the four clusters and 
the cellular markers expressed by each cluster is shown in Table 4. 
 
Table 4. Four cellular clusters identified after mass cytometry and their expression of cellular markers 
 without cGVHD vs. mild cGVHD moderate vs. severe cGVHD 
B cells 
cluster 399970 cluster 399948 
CD19+ CD39+ CXCR5+ HLA-DR+ 
CD38+ Ki-67+ CD19+ CD39+ CXCR5+ HLA-DR+
 
(NK) T cells 
cluster 399954 cluster 399981 
CD3+ CD57+ GzB+ 
CD8low PD-1low CCR4+ 
CD3+ CD57+ GzB+ 
CD8low PD-1low 
 
The four clusters could be confirmed in smaller flow cytometry panels in patients from the 
second cohort. For this confirmation, we picked 9 of the 33 markers that we deemed to be 
most indicative of the cluster of interest. Nine markers were the maximum number we 
could analyse by flow cytometry. Moreover, we wanted to analyse as many dimensions as 
possible to try to mimic the high dimensional analysis of mass cytometry. We used Boolean 
gating to identify the clusters. Boolean gating entails that you gate for all markers on a 
major cell subset. After you are satisfied with the gates, the software then calculates the 
frequency of cells that would fit in all of the gates you tell it to incorporate in the 
calculation. This avoids any user bias you might encounter in conventional sequential 
gating. In sequential gating, you gate for one subset, display the subset and then gate for the 
next subset, etc. The user can adjust the gates as they see fit, which can make the subsets 
more accurate but, especially if the user is not blinded to the data, bias may occur. Hence, 
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we decided to start our flow cytometric analysis using Boolean gating and also perform 
sequential gating where needed.  
 
Patients without cGVHD and patients with mild cGVHD were different in the abundancy of 
cluster 399954, a (NK)T cell subset and 399970, a B cell subset (Figure 16). Cluster 
399954 was found at a lower abundancy and cluster 399970 in a higher abundancy in 
patients without cGVHD. Cluster 39954 was thought to be either an activated cytotoxic T 
cell or an NKT cell subset. The cells in this cluster expressed CD3, CD57, CCR4, 
granzyme B and to a lower extent CD8 and PD-1 (Figure 16A). As we did not include any 
specific NKT cell marker in the mass cytometry, nor did we have space to do so in the 
confirmatory flow panel, we cannot state for sure whether these cells are NKT cells or 
activated cytotoxic T cells. Cytotoxic T cells can also express CD57 and upon activation 
reduce expression of CD8.280, 281 Since we previously identified differences between 
patients without cGVHD and mild cGVHD in CD38-expressing cytotoxic T cell 
frequencies in the first cohort, we hypothesise that it is likely that the cells in cluster 
399954 are also activated cytotoxic T cells.  
 
 
 
Figure 16. Mass cytometry and confirmatory flow cytometry results of two clusters that varied significantly between 
patients without cGVHD and patients with mild cGVHD. 
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In the confirmatory flow cytometry, we identified cluster 399954 by Boolean gating for a 
positive expression of CD3, CD57, granzyme B and CCR4, and a dim to negative 
expression of CD8 (Figure 16B). Similar to the mass cytometry results, patients with mild 
cGVHD had a higher frequency of these cells than patients without cGVHD. This indicates 
a more cytotoxic T cell phenotype in patients with mild cGVHD. 
 
Unfortunately, cluster 399954 did not express CD38, hence the CD38+ cytotoxic T cells we 
identified, as discussed before, are not the same cells as those in cluster 399954. These are 
two distinct cellular subsets that differ between patients without cGVHD and mild cGVHD. 
However, both findings point towards a general activation of the cytotoxic T cells in 
patients with mild cGVHD. 
 
The second cluster (399970) was considered to be a B cell subset, as it was positive for 
CD19. Moreover, the cells in this cluster also expressed CD38, CD39, CXCR5, HLA-DR 
and Ki-67 (Figure 16A). This would suggest an activated B cell subset undergoing 
proliferation. Unfortunately, we encountered problems with the Ki-67 staining in the 
confirmatory flow cytometry panel. We speculate this was due to using a too mild 
intracellular staining protocol. For fear of destroying epitopes on the cell surface, we may 
have used a too mild detergent, making it impossible for the Ki-67 antibody to enter the 
nucleus. Though we could still identify the cluster in flow cytometry by Boolean gating for 
CD19, CD38, CD39, CXCR5 and HLA-DR, we could not detect differences in this 
population between patients without cGVHD and patients with mild cGVHD. Hence, we 
also performed conventional sequential gating for flow cytometry. 
 
We identified a difference in populations between the two patient groups when analysing 
CD38 expression on CD39+ CXCR5+ HLA-DR+ B cells (Figure 16C). This subset was 
found at a higher frequency in patients without cGVHD, comparable to the mass cytometry 
results for cluster 399970 (Figure 16A). This finding is in contrast to findings of a recent 
study where they correlated high frequencies of CD38hi plasmablasts with ongoing 
cGVHD.265 However, that study incorporated patients with varying grades of cGVHD with 
most having severe cGVHD. Our cohort included only patients with mild cGVHD or no 
cGVHD. Additionally, since we did not include CD24 in our analysis, it is not possible to 
say whether the subset we identified constituted of plasmablasts. We conclude that the 
subset we identified is a novel subset that may be worthy of further research.  
 
Looking at the markers expressed, we hypothesise that these are recently activated B cells 
that might have some form of regulatory function. Even though CD39 has not been linked 
to B cell regulatory function before, it has been linked to T cell regulatory function and 
might have a similar function in B cells.282, 283 It would be interesting to sort these cells by 
flow cytometry and culture them to see whether they have any regulatory capacity in vitro. 
This was not possible within the scope of this study, but might be possible in a follow-up 
study with a new cohort of patients. 
 
We also performed mass cytometry on samples from patients with moderate and severe 
cGVHD. These patient groups were found to differ in the abundancy of cluster 399948, a B 
cell subset and 399981, another (NK) T cell subset (Figure 17A). Both clusters were more 
abundant in patients with severe cGVHD. Strikingly, though not exactly the same, both 
clusters resembled the previously described clusters in patients without cGVHD and mild 
cGVHD (Figure 16).  
 
The clusters were identifiable via Boolean gating but were not different between patients 
with moderate and severe cGVHD. Due to low sample availability at the time the 
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confirmatory flow cytometry was performed, we expect that the lack of statistical 
significance is mostly due to low power. However, as mentioned before, the effect of high 
immunosuppressant drugs given for long periods to these patients may also explain the lack 
of differences between these groups. 
 
I will discuss the clusters one by one. Cluster 399948 (Figure 17A), resembled cluster 
399970 (Figure 16A). The B cells in cluster 399948 also expressed CD39, CXCR5 and 
HLA-DR, but not CD38. Another difference between these clusters is that cluster 399948 
was expressed at a higher frequency in more severe cGVHD, while cluster 399970 was 
expressed at a higher frequency in patients without cGVHD. These two B cell subsets are 
distinct from each other but since they co-express quite a few markers it would be 
interesting to further analyse them side by side. As these subsets are not well studied, it is 
hard to speculate how they might function in cGVHD development. 
The second cluster that differed between moderate and severe cGVHD patients by mass 
cytometry was cluster 399981 (Figure 17A). This cluster resembled cluster 399954 (Figure 
16A). Cluster 399981 expressed CD3, CD57, granzyme B and, to a lesser extent, CD8 and 
PD-1. When performing the sequential gating for this cluster in the confirmatory flow 
cytometry, we identified a reversed significant difference between the groups. In the mass 
cytometry, this cluster was found in higher abundancies in severe cGVHD patients. In the 
confirmatory flow cytometry though, we identified a reduced frequency of CD8 expressing 
Figure 17. Mass cytometry and confirmatory flow cytometry results of two clusters that varied significantly between 
patients with moderate and severe cGVHD. 
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Granzyme B+ CD57+ T cells in patients with severe cGVHD (Figure 17C). This difference 
in mass cytometry and flow cytometry results could be due to sample size or it could be due 
to the fact that in the mass cytometry 33 markers contributed to the identification of the 
cluster, while in the flow cytometry, the population was identified by just 4 markers. The 
population identified by mass cytometry may be a smaller subset of the population 
identified by flow cytometry. As such the frequencies may be inverted. Interpreting the 
results of the flow and mass cytometry is difficult. While it may seem contradictory to have 
less cytotoxic T cells in blood in patients with more severe cGVHD, we speculate that the 
cytotoxic T cells might have migrated towards the inflamed tissue, similarly to the MAIT 
cells, as discussed before. This is something that should be explored by analysing biopsies 
from patients. Until then, we can only speculate on whether this finding is truly something 
involved in the pathophysiology of cGVHD or simply a bystander effect of the disease.  
 
The mass cytometry findings could, to a large extent, be confirmed in smaller flow 
cytometry panels. Due to sample availability, the confirmatory flow cytometry panels may 
have been underpowered and may explain why we could not confirm all clusters or only 
confirm them by sequential gating. Most importantly we feel that it is possible to use multi-
dimensional methods to identify novel subsets, which may then be converted and used in 
more routine settings.  
 
There is one important aspect of cGVHD that we have not discussed in Paper II. In the 
paper, we compared patients with moderate to severe cGVHD. However, all moderate 
cGVHD patients and all severe cGVHD patients are not alike. As cGVHD can manifest in 
many different organs, these patients could also be split by cGVHD organ involvement 
instead of total severity. For instance, compare patients with lung-associated cGVHD to 
patients without lung-associated cGVHD. This type of analysis was not performed in the 
paper, however, it is something that we are currently working on. As we are interested in 
diagnostic markers, the mass and flow cytometry results could help identify markers that 
would help identify affected organs.  
 
To illustrate, preliminary findings indicate a 
reduced frequency of MAIT cells in the blood of 
patients with GI tract-affected cGVHD 
regardless of moderate or severe cGVHD 
classification (Figure 18). This is in line with the 
hypothesis that MAIT cells migrate towards the 
affected GI tract.  
 
Additionally, before mass cytometry was 
performed, half the sample was stimulated with 
PMA and ionomycin. Hence, we can also 
analyse the differences between patient groups 
when their lymphocytes are activated in terms of 
cellular markers and cytokine production. We 
are currently analysing these results. 
 
In this study, we aimed to identify potential 
diagnostic markers for cGVHD and gain insights 
into the pathophysiology of cGVHD. Since we 
did not analyse our results in a completely 
independent second cohort, we cannot say with 
certainty that the markers identified are truly 
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biomarkers. As described in detail in the 2014 report of the NIH cGVHD biomarker 
working group, biomarkers need to be confirmed in at least two independent cohorts.284 
Hence, our results need to be validated in another cohort before they can be considered 
biomarkers.  
 
However, they do shed some light on the pathophysiology of cGVHD. For instance, there 
appears to be a role for MAIT cells in both aGVHD and cGVHD. Though they are a small 
subset in blood, frequency variations appear to have some predictive value in aGVHD and 
diagnostic value in cGVHD. Thus, we conclude that MAIT cells may have a function in 
GVHD development. One suggested function is migration towards inflamed tissue to exert 
an effector function there. It is unclear whether they have a dampening or a pro-
inflammatory effect. More research into this is needed. One first step would be to analyse 
biopsies, preferably both inflamed and non-inflamed parts of tissue from the same patient. 
This would indicate whether MAIT cells are recruited to inflamed tissue or not. 
 
Perhaps the most intriguing aspect of the cGVHD study is the possibility to use 
multidimensional methods to discover novel subsets. In this study, the mass cytometry 
results could be interpreted and translated into smaller flow cytometry panels. 
Unfortunately, we could not identify all of the same differences in these smaller flow 
cytometry panels. We feel that small sample size could be a factor in the lack of statistical 
significance.  
 
Similar as for Paper I on aGVHD, we feel that the results are interesting and worthy of 
further research. As such, several future steps should be taken to further elucidate and 
confirm these findings. We will discuss some of these in the “concluding remarks and 
future aspects” section. 
 
To conclude, this part of the discussion has focused on two complications where graft and 
recipient co-existence does not work as intended. A war has broken out between the graft 
and the recipient. They are two different types of war. Acute GVHD could be seen as a fast 
and overwhelming invasion and destructive war. Chronic GVHD on the other hand is 
slower, stays under the radar for longer and is more of a long-lasting, exhaustive occupation 
type of war. Fortunately, there are also a lot of patients where these severe grades of 
aGVHD and cGVHD do not occur and who do well post-HSCT. The fact that some patients 
do not suffer from these severe diseases is one of the main reasons why HSCTs are still 
performed and why so much research is put into elucidating the mechanism behind the 
complications. A better understanding will hopefully improve the HSCT treatment, 
resulting in more and more patients who do not need to suffer from GVHD. Compared to 
HSCT outcomes of just a decade ago, globally, HSCTs have benefited from the efforts of 
researchers around the world, as severe grades of GVHD are slowly decreasing in almost 
all centres.  
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4.2 MIXED CHIMERISM: CO-EXISTENCE TO THE EXTREME 
In broad terms, when we talk about the co-existence of the donor graft-derived immune 
cells and the recipient cells, we refer to the immune tolerance of the graft to the recipient. 
However, post-HSCT, in MC there is not only a tolerance of the donor-derived 
hematopoietic system towards the patient tissues, there is also a tolerance of the patient’s 
own recipient hematopoietic system towards the donor’s. This is a quite extraordinary 
phenomenon that most often only occurs early post-HSCT. Usually the donor-derived 
hematopoietic system triumphs in the end, be it on its own or helped by DLIs. However, 
there are special cases where long-term stable MC occurs and persists. These patients are 
still mixed chimeras even several years post-HSCT.  
 
Long-term stable MC has not been studied to a great extent or detail. At our centre we were 
fortunate to have an extensive patient database and practice of regularly performing 
chimerism analyses on all transplanted patients. Hence, we could identify a cohort of living 
patients displaying stable MC more than 5 years post-HSCT.  
 
One major limitation of the study is that we only included patients still alive at least 5 years 
post-HSCT. It is possible that we introduced a selection bias by recruiting patients in this 
way. The only option to avoid this is to include patients from the time of HSCT and 
following them prospectively. This was not possible for the scope of this PhD programme.  
 
Since not much is known about these rare patients with long-term stable MC we decided to 
analyse them further to see if we could elucidate the development of MC. Our specific aim 
for the study, as presented in Paper III and IV, was to gain insight into the mechanism 
behind long-term stable MC in patients that underwent HSCT to treat non-malignant 
disorders. Our patient cohort with MC was compared to the control group; a cohort 
matched for age, disorder, gender and time post-HSCT who displayed stable DC. We 
attempted to elucidate the immune phenotype and function of the hematopoietic systems in 
these two patient cohorts. We aimed to answer questions such as whether MC affects the 
patients’ quality of life and whether both hematopoietic systems were functional or not.  
 
The study started by comparing the two patient groups for clinical parameters to identify 
whether we could find any clinical factors associated with MC development. As discussed 
in detail in Paper III, most clinical characteristics were similar for the two patient groups. 
We identified a significant difference in donor type, i.e., HLA-identical sibling or HLA-
(mis)matched unrelated, between the patient groups (p=.005). Patients who developed MC 
were more likely to have an HLA-matched sibling donor than patients with DC. Moreover, 
patients with MC received grafts from younger donors (p=.017), a phenomenon also 
previously described in the literature.285 However, as donor age and donor type are likely to 
be correlated, we performed a multivariate statistical analysis. This demonstrated that donor 
type was more associated with MC development than donor age.  
 
Additionally, patients with DC were more prone to develop aGVHD than patients with MC. 
Grade II or more severe aGVHD has previously been identified as predictive of DC.174, 285-
288 Higher incidence of aGVHD in patients with DC could also be linked to differences in 
donor type between the patient groups as HLA-identical sibling donors are more likely to 
be matched also on minor histocompatibility antigens than matched unrelated donors. 
Hence, we performed a multivariate analysis on the effect of donor type and aGVHD on 
MC development. Again, donor type was more important for MC development than 
occurrence of aGVHD. 
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We concluded that a sibling donor was positively correlated to MC development. This is 
not entirely a surprising result. As mentioned, sibling donors are usually more matched on 
minor histocompatibility antigens than unrelated donors. As such, the new (donor) and the 
old (patient) hematopoietic systems are less likely to recognize each other as non-self. If 
they do not recognize each other as non-self, they are more likely to tolerate each other and 
co-exist peacefully. 
 
This finding in itself can be considered promising news for the solid organ transplantation 
field. As mentioned in the introduction section, that field is highly interested in MC. Quite a 
few studies have attempted to develop a transient MC in a patient before an organ is 
transplanted.178-181 The idea is to induce tolerance in the patients hematopoietic system to 
the donor organ during the period of MC. After some time the donor hematopoietic system 
will be rejected and the hope is that the patient’s immune system will no longer recognize 
the transplanted organ as foreign. The patients would not need to be on immunosuppressive 
drugs for the rest of their lives. This procedure would primarily be an option for living 
donor solid organ transplantations especially if MC needs to be developed days or weeks 
prior to the organ transplantation. Living donor organ transplantations often use solid 
organs from a first degree relative. As such, identifying sibling donors as playing a major 
role in MC development could be interesting for the solid organ transplantation field.  
 
Interestingly, we also identified a potential role for HLA-C in MC development. HLA-C 
mismatches have been associated with poor HSCT outcome.289, 290 However, in a recent 
study in our centre, no adverse effect on HSCT outcome was observed for patients 
transplanted with HLA-C mismatched grafts.291 In Paper IV we observed that patients with 
DC received grafts with more HLA-C mismatches than patients with MC. As HLA-C 
mismatches are more likely to occur in unrelated donors than in HLA-identical sibling 
donors, it is yet again a sign for the important role of sibling donors in MC development. 
 
HLA-B18 was also identified as having a putative role in the development of MC. None of 
the patients with MC had an HLA-B18 allele, while almost a third of the patients with DC 
did (p=.039; Paper III). The reason for this is hard to pin down. As far as we are aware this 
HLA-allele has not been linked to chimerism or any other outcome post-HSCT. It has been 
linked to other disorders, such as lymphoproliferative disease after solid organ 
transplantation292, skin squamous cell carcinoma after renal transplantation293, and type 1 
autoimmune hepatitis294. However, the link to chimerism post-HSCT is not entirely clear. It 
could be due to chance as the patient groups were quite small. Further research in larger 
patient groups could potentially clarify this.  
 
The two patient groups were also compared for quality of life parameters, e.g., rate of 
infections, ability to work, etc. Strikingly, patients with MC were equally well or arguably 
better off than patients with DC for several parameters after HSCT. For instance, 
immunisation response to vaccinations was similar between the two patient groups (Paper 
IV). Also, none of the patients with MC developed blood stream infections (BSIs) post-
HSCT, while this occurred in almost a third of the patients with DC (p=.039; Paper III). 
However, the study design did not allow us to elucidate whether the BSIs were due to DC 
development or vice versa. Moreover, more than 5 years post-HSCT, the two patient groups 
were similar in terms of infection rate, medication usage, ability to work or study fulltime, 
sick leave and other quality of life parameters (Paper IV).  
 
We conclude that while there may be some differences between patients with MC and DC 
in terms of infections early post-HSCT, the patient groups are quite similar in the long-
term. Patients with MC do not seem to suffer unduly from being mixed chimeras.  
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Despite similar quality of life post-HSCT, MC is seen as detrimental in some centres. As 
such it is often treated with DLIs to force the donor hematopoietic system to take over. 
However, DLIs are not without risk, being linked to GVHD development in most studies, 
especially when given in bulk dose rather than an escalating dose.152, 295-297 Since aGVHD 
is not desirable, especially in patients with non-malignant disorders, we argue that DLIs 
should not be given immediately after MC is observed. Instead, we suggest patient 
monitoring to make sure the MC stabilizes. If it does not stabilize, it may indeed indicate 
graft rejection, especially shortly post-HSCT, and then DLIs should be given. However, if 
the MC stabilizes and/or if the patient is many years post-HSCT without any adverse 
symptoms, perhaps nothing should be done. If a long-term stable MC develops it may not 
necessarily be a bad thing. These patients are likely to develop less aGVHD, less blood 
stream infections and are in good shape in the long term. 
 
To understand MC better, we decided to immune phenotype them extensively. Similarly, as 
for the studies described in Paper I and Paper II, we looked at soluble and cellular 
characteristics of the patients at time of inclusion in the study (Paper IV). 
 
Patients with MC had lower plasma levels of IL-4, IL-12 (p40) and G-CSF. One of the 
most straightforward explanations could be that patients with MC have a higher cell 
turnover and thus a higher cytokine consumption. For instance, this could be possible in the 
case of infections. However, as the patient groups did not differ in infection rate or other 
cytokine levels, this seems unlikely. Another explanation could be that patients with MC 
have a slightly lower inflammatory environment than patients with DC. This seems likely 
as IL-12 (p40) is a classic pro-inflammatory cytokine and reduced levels would indicate a 
less inflammatory environment. Though the patient groups had similar infection rates at 
time of inclusion, patients with DC did suffer more inflammatory conditions early post-
HSCT than patients with MC, e.g. more aGVHD and blood stream infections.  
 
While it is hard to say exactly why these three cytokines were lowered in patients with MC, 
it is interesting to see how they correlate with other findings in the patients with MC. For 
instance, G-CSF is known to suppress platelet function184-186, 298, and as such we expect 
patients with MC to have more platelets than patients with DC. Indeed, patients with MC 
had increased platelet counts while white blood cell and neutrophil counts were similar. As 
this difference in platelet count was small (MC 239.000 platelet/mL vs. DC 198.000 
platelets/mL), it is unlikely to hold true clinical value. It is difficult to see how this small 
difference could impact the patient.  
 
Plasma levels of IL-4 were also lower in patients with MC. IL-4 is known to stimulate Th2 
differentiation.299, 300 Hence, patients with MC with a lowered IL-4 level should be more 
skewed towards a Th1 phenotype as compared to patients with DC. One of the main 
cytokines produced by Th1 cells, IFNg, has been shown to promote B cells to class switch 
towards IgG3. Moreover, the same study demonstrated IL-4 directly inhibited expression of 
IgG3.301 As such we would expect increased levels of IgG3 and IFNg in patients with MC. 
Even though IFNg levels were similar between the patient groups, we did observe an 
increased level of IgG3 in patients with MC (Figure 19). 
 
To the best of our knowledge, IgG and specifically IgG3 levels have not previously been 
linked to DC. It has been negatively associated to donor-specific HLA antibodies and AB0 
mismatching in (solid organ) transplantation302-304, though there was no correlation between 
high IgG3 and AB0 mismatches in the patients with MC in this study. Patients with an 
above median IgG3 level were AB0 matched, had high Karnofsky performance status and 
did not have any indications of autoimmune diseases. Hence, the IgG3 increase does not 
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seem to be related to an allo-mediated response. It 
could simply be due to the observed lowered levels 
of IL-4. Even though IgG3 is negatively linked to 
solid organ transplantation outcomes, other studies 
identified a potential protective role for IgG3. A 
quite recent study discussed a case report of an adult 
patient suffering from recurring herpes zoster virus 
infection due to an IgG3 deficiency.305 Another study 
reported severe recurring infections in 6 children 
with IgG3 deficiencies.306 Though these cases are not 
comparable to the situation post-HSCT in this study, 
it is worth noting again that the patients with DC 
with lower IgG3 levels suffered from more 
infections early post-HSCT than the patients with 
MC did. Even though the infection rate was similar 
at time of inclusion in the study, we can speculate 
that perhaps patients with MC were still slightly 
more protected against infections than patients with 
DC due to increased IgG3 levels. 
 
Interestingly, IgG3 was also positively correlated to platelet counts in patients with MC. 
Hence, platelet counts, and with it G-CSF levels, are linked to IgG3 and IL-4. In our 
experimental set-up it is impossible to state if the increased levels of IgG3 were due to the 
lowered levels of IL-4 or due to another reason. At the moment, we do not know which 
phenomenon came first, IgG3, platelets or IL-4. To be sure, longitudinal follow-up and 
immune phenotyping is needed.  
 
Unfortunately, the reduced levels of IL-12 (p40) may complicate matters a bit more than I 
first let on. As stated, IL-12 (p40) is a pro-inflammatory cytokine and lower IL-12 (p40) 
levels thus fit the less inflammatory environment hypothesis of patients with MC. 
Moreover, IL-12 (p40) is also known to stimulate cells to produce IFNg.307 As discussed 
previously, IFNg can induce B cells to switch to IgG3. However, IL-12 (p40) can also 
promote Th1 cell differentiation and is important for NK cell function.308, 309 Hence, 
patients with MC should be less skewed towards a Th1 phenotype. This is in contrast to 
what we speculated earlier, regarding the finding of low IL-4 levels skewing these patients 
towards a more Th1 phenotype. Moreover, NK cell frequencies were similar between the 
patient groups in contrast to what we might have expected due to the difference in IL-12 
(p40) levels. The only thing close to an NK cell phenotype difference was an increase in 
CD56+ CD8+ and CD94+ CD8+ T cells in patients with MC. This subset is either an NKT 
cell subset or an activated CD8+ T cell subset. Since no additional markers were added to 
specify further, we unfortunately cannot say for sure. As mentioned in the cGVHD study, 
CD8+ T cells can express CD56/CD57 and not be classified as an NKT cell.280, 281, 310 
Additional markers are required for confirmation.  
 
Cytokines are part of an intricate and complex process. They influence each other making it 
difficult to truly understand the impact of single cytokine levels as a whole. No single 
cytokine is the most important. Hence, while it seems likely that patients with MC have a 
slightly less inflammatory environment than patients with DC, it is hard to say this for sure 
as some results can be interpreted in conflicting ways. As mentioned, a longitudinal follow-
up and larger cohorts are needed.  
 
IgG3
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Figure 19. IgG3 levels in patients with full 
donor chimerism (DC) and mixed chimerism 
(MC). 
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The patient groups were also compared for cellular immune phenotype and were found to 
be quite similar. The only differences observed between the groups were platelet counts and 
the increased frequency in CD56+ CD8+ and CD94+ CD8+ T cells, as mentioned in the 
previous paragraphs. The major cellular subsets, such as T cells, B cells and NK cells were 
the same. The radar graphs in Figure 20 demonstrate the similarity for these cellular subsets 
in the patient groups. 
We also looked at the protein expression of certain key proteins in the T cell activation 
cascade by western blot. As we could not separate the cells prior to analysis, the western 
blot was performed on whole lymphocyte populations. Two of the proteins analysed 
showed interesting results, ZAP-70 and LCK. The function of both proteins in the T cell 
activation cascade has been discussed in the relevant introduction section. ZAP-70 was 
found at lower levels in patients with MC compared to patients with DC. LCK levels were 
similar between the patient groups. Both proteins are vital in the activation cascade. A 
reduced expression of ZAP-70 or LCK has been linked to T cell anergy.21, 311, 312 As such, it 
can be argued that the reduced levels of ZAP-70 in patients with MC may dampen T cell 
activation, as they have a reduced ability of TCR signalling. This may affect their ability to 
react to antigens. Since the patients are seemingly still able to react to common pathogens, 
perhaps the reduced signalling contributes towards the tolerance between the two immune 
systems. They may still respond to strong signals from pathogens. However, weaker signals 
from patient and donor antigens, seeing as how the vast majority of the patients with MC 
were HLA matched, may not be sufficient to initiate an effective TCR signalling cascade. 
To determine whether reduced ZAP-70 levels could drive tolerance between the systems or 
whether it is merely a symptom of tolerance after it has developed, one would need to find 
out when the reduced level of ZAP-70 emerges post-HSCT. Is this a phenomenon that 
occurs early post-HSCT or does it appear after a stable long-term MC has developed? 
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Moreover, is the ZAP-70 deficiency present in only the patient- or only the donor-derived 
lymphocytes, or in both? While we cannot be sure, we hypothesise that the lowered ZAP-
70 expression was present in both patient- and donor-derived lymphocytes. Irrespective of 
whether a patient with MC had a high recipient chimerism (predominantly recipient cells) 
or a low recipient chimerism (predominantly donor cells), ZAP-70 expression was lowered 
in patients with MC. Thus, it seems likely that both donor- and recipient-derived cells had 
lower ZAP-70 expression in patients with MC, maybe indicating a global tolerant state of 
the lymphocytes.  
 
To better understand the impact of the protein expression and as a functional indicator of 
the hematopoietic cells, we decided to see if we could correlate the findings to immune 
phenotype. While ZAP-70 expression was different between patients with MC and DC, it 
was not correlated to immune phenotype for either patients with MC or DC. On the other 
hand, LCK which was similar between the groups, was correlated to immune cell 
phenotype of patients with MC. 
 
LCK expression correlated to a higher frequency of effector memory cells in the CD4+ T 
cell and total ab T cell compartment (Figure 21). Strikingly, this difference was not 
observed in CD8+ T cells. As far as we are aware, both CD8+ and CD4+ T cell activation 
requires LCK involvement. To complicate matters further, gd T cells displayed the reverse 
correlation pattern for LCK and effector memory phenotype. Effector memory gd T cells 
were correlated to less LCK expression. As gd T cell activation and memory differentiation 
is still not elucidated entirely, we can only hypothesise as to the cause of the reversed LCK 
expression pattern in these cells. One explanation could be that these non-conventional T 
cells have different downstream signalling kinetics upon activation than ab T cells, making 
them less dependent on LCK and ZAP-70 expression.313, 314Another explanation could be 
that the classical method of identifying effector memory T cells by CCR7 and CD45RO 
expression does not suit gd T cells.  
 
Another way to determine functionality is to stimulate lymphocytes and measure activation 
and cytokine production. We performed a stimulation experiment with PMA and 
ionomycin. As discussed in the methods section, this will stimulate lymphocytes. The cells 
were stimulated for four hours and then IFNg and IL-2 production was measured. For 
optimal IL-2 production, slightly longer stimulation times are usually recommended but 
this was not possible due to sample availability.315 
 
Patients with MC and DC had similar cytokine production regardless of gating on total T 
cells, CD4+ T cells, CD8+ T cells or memory (CD45RO+) T cells after PMA stimulation. 
We did see a difference in patients with MC and DC in the control experiment which was 
incubated for four hours without stimuli. This can be seen as the baseline cytokine 
production, similar to the unstimulated setting in the aGVHD study in Paper I. Patients 
with MC produced more IL-2 when unstimulated than patients with DC for all the 
aforementioned cellular subsets. No differences were seen in IFNg production. The 
frequencies of IL-2 producing cells were quite low (1-4% depending on the subset), which 
is to be expected in an unstimulated control.  
 
It is surprising that patients with MC had a higher IL-2 steady state production than patients 
with DC. IL-2 has been shown to promote T cells towards effector memory phenotypes.316 
As there was a correlation between effector memory phenotype and LCK in patients with 
MC, we hypothesised that there might also be correlation between LCK and IL-2 
production. Indeed, we could detect correlations between LCK and IL-2 & IFNg or only 
IFNg producing CD4+ T cells (Figure 22). We could not detect a correlation for CD4+ T 
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cells only producing IL-2 nor did we find a direct correlation between cytokine production 
and effector memory phenotype. It is not easy to conclude why we could not correlate IL-2 
only producing cells to LCK or directly to effector memory phenotype. It could be because 
LCK expression was measured on total lymphocytes and that the cytokine production was 
limited to smaller cellular subsets. Additionally, it is likely that the sample size of these 
experiments limit the ability to draw firm conclusions. 
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Figure 21. Memory differentiation correlated to LCK expression in mixed chimerism (MC) patients. 
Two different regression analysis methods were used, as there is no unified linear regression method 
best suited for non-normal data. The dotted line indicates the least squares fit linear regression analysis 
and the solid line indicates the robust fit linear regression analysis. 
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To understand MC development better we looked at patients with MC in more detail. We 
started with investigating how patients developed MC over time. To this end, we collected 
chimerism analysis results performed for these patients over the years post-HSCT for T, B 
and myeloid cells in blood (Figure 23).  
 
In general, frequencies of recipient-derived cells fluctuated the most during the first couple 
of years. To find out if these fluctuations were true fluctuations and not merely due to the 
effect of multiple chimerism analyses during the first years and only occasional analyses 
later years post-HSCT, we calculated the relative fluctuations for three different time 
periods post-HSCT. By dividing the sum of the fluctuations by the number of times 
chimerism analysis was performed during the period of interest, we could demonstrate a 
significant increase in fluctuations in the 0-2 years period post-HSCT as compared to the 2-
3 years period post-HSCT (Paper III). Thus, patients became more stable in their MC 
status over time. We hypothesise that this is in part due to the fact that the first couple of 
years are turbulent. Patients have undergone extensive conditioning regimens, engrafted an 
entire new hematopoietic system and can become sick with aGVHD, cGVHD and 
infections. It is possible that as the patient undergoes such intense events, the interaction 
between patient- and donor-derived hematopoietic systems are affected as well. The 
patients with MC need time to develop a calmer, less inflammatory environment before 
stable MC can develop. In some patients, the fluctuations already flatten out as early as 1-2 
years post-HSCT, while in others it can take up to 5 years post-HSCT. 
 
Another interesting finding was that the fluctuations were not necessarily uniform between 
cellular subsets. For instance, T cell frequencies fluctuated much more than B cells. This is 
partly due because T cells engraft much faster than B cells. However, it could also indicate 
a T cell mediated role in developing tolerance. For instance, patients who developed long-
term stable MC were less likely to have blood stream infections and aGVHD development 
post-HSCT. We could speculate that if there are less infections and no aGVHD, there are 
less danger signals and costimulatory signals for the donor-derived hematopoietic cells to 
respond to. Thus, the donor-derived hematopoietic cells are less inclined to respond to 
recipient-derived cells in a negative way. Moreover, as patients with MC were more likely 
to receive grafts from HLA-identical siblings, fewer histocompatibility mismatches make it 
less likely for the donor-derived hematopoietic cells to negatively react to recipient cells. 
The reverse is also true for the remaining recipient-derived hematopoietic cells. The lack of 
costimulatory signals and histocompatibility mismatches may make them less likely to react 
to the donor-derived hematopoietic cells. Thus, tolerance is born and with it stable MC. 
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Figure 22. Cytokine-producing CD4+ T cells correlated to LCK expression in mixed chimerism (MC) 
patients. Two different regression analysis methods were used, as there is no unified linear regression 
method best suited for non-normal data. The dotted line indicates the least squares fit linear regression 
analysis and the solid line indicates the robust fit linear regression analysis. 
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These chimerism analyses indicate that in broad terms, patients with MC are chimeric for 
the major immune cell subsets; i.e. T, B and myeloid cells. It does not tell us whether the 
recipient- and donor-derived hematopoietic systems are fully present or whether they have 
found niches within the immune system. For instance, perhaps all gd T cells are of recipient 
origin and all ab T cells are of donor origin. To answer this, we sorted additional cellular 
subsets by flow cytometry and performed additional chimerism analyses. This showed that 
CD4+ T cells, CD8+ T cells, gd T cells and NK cells in almost all patients with MC were of 
donor and recipient origin (Figure 24). In general, the frequencies of these four cell subsets 
followed the trend of total T cells, e.g., if a patient had a high frequency of recipient-
derived T cells, the frequency of recipient-derived cells for these four other subsets was 
high as well. Unfortunately, due to limitations in sample availability, we could only sort 
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Figure 23. Chimerism pattern for 12 mixed chimerism (MC) patients post-HSCT.  
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these four subsets. However, it does indicate, that on a slightly deeper level, patients with 
MC are still mixed. They appear to have both recipient- and donor-derived cells in all 
subsets.  
 
The next question now was whether all cells were functional. Can both recipient and donor-
derived cells be activated and produce cytokines? As patients with high recipient chimerism 
(predominantly recipient cells) were capable of fighting of pathogens, we expected that 
their recipient cells should retain some functionality. However, would that truly be so, and 
how would the recipient cells of patients with low recipient chimerism (predominantly 
donor cells) behave? To answer this, we performed a stimulation experiment with PMA and 
looked at IFNg and IL-2 production. After stimulation, we sorted total T cells for their 
production of IFNg and IL-2 (Paper IV) and then performed another chimerism analysis on 
the sorted populations. Unfortunately, we could not sort enough cells for all patients with 
MC. However, the patients we could analyse showed that almost all had both donor and 
recipient cells capable of producing cytokines (Figure 24). It is striking to see that some of 
the patients with low recipient chimerism (for instance, unique patient number (UPN) 527, 
615 and 921) retained functionality in recipient cells. 
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Figure 24. Chimerism results at time of inclusion for additional cellular subsets. 
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It would appear that not only are recipient cells present in most cellular subsets, they are 
also functional. One could still argue that the subsets we assessed are quite big and 
encompass many smaller cellular subsets. It is possible that smaller subsets are completely 
recipient or donor. To ascertain this, a follow-up study is needed wherein we could 
stimulate the cells with other substances, for instance viral antigens or E. coli. Additionally, 
we could try and sort for more special cell subsets, such as MAIT and NKT cells. 
 
To conclude this section on the special phenomenon of tolerance between graft and the 
recipient, I feel that I need to stress again that this research was performed on small groups 
and on limited samples. These patients are rare and in good shape. As such they do not need 
regular check-ups and we had to ask them for samples specific for this study.  
 
That being said I feel that this study has improved the knowledge on MC development. If 
nothing else, we proved that these patients are in good health post-HSCT and are not 
negatively affected by having two hematopoietic systems. Moreover, it seems that both 
systems are active and capable of responding to stimuli. I propose that these patients may 
need monitoring to ensure they do not reject the graft, especially during the first months 
post-HSCT. However, a stable MC in patients with non-malignant disorders may not 
always require intervention. As discussed, DLIs increase the risk for GVHD, which is not 
desirable for non-malignant disorders. In fact, some of the patients with MC in this study 
received DLIs shortly post-HSCT, however, they remained mixed chimeras. Hence, we 
conclude that MC may not be the unequivocal villain as it is sometimes seen as in the 
HSCT field. In some patients, it may be considered a vigilant friend.  
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5 CONCLUDING REMARKS & FUTURE PROSPECTS 
For a successful HSCT, donor graft- and recipient-derived cells need to learn to tolerate 
each other. Most importantly, the donor-derived cells must learn to tolerate recipient tissue. 
In some cases, this learning process does not go smoothly and GVHD develops. In other 
exceptional cases, a long-term stable MC develops wherein not only do the donor-derived 
cells tolerate the recipients’ cells, recipient-derived hematopoietic cells also tolerate the 
donor graft.  
 
In this thesis, I tried to elucidate some of the mechanisms of these immunologic events 
post-HSCT and especially in the case of GVHD, to identify potential predictive and 
diagnostic biomarkers.  
 
 
5.1 SPECIFIC CONCLUSIONS 
• Clinically, predictive biomarkers for grade II-IV acute GVHD are needed. Most 
research groups have focused on markers in patient specimens. While difficult, I show 
that it is possible to identify potential predictive markers in the donor grafts.  
 
o Patients with grade II-III aGVHD received donor grafts with lower 
frequencies of MAIT cells. 
o In grade II-III aGVHD development there is a potential role for high 
frequencies of PD-1 and low frequencies of CD127-expressing T cells in the 
donor graft.  
o Increased levels of TNFa in both patient blood and the donor graft could be 
linked to grade II-III aGVHD development. 
 
• Similar to acute GVHD, there is a clinical need for diagnostic biomarkers for severe 
grades of chronic GVHD. Identifying biomarkers for chronic GVHD development 
using standard laboratory techniques is difficult.  
 
o Patients with pronounced severity of chronic GVHD appear to have less 
MAIT cells in the peripheral blood. 
o New multidimensional techniques such as mass cytometry can discover novel 
cellular subsets (B and NKT) that may play a role in chronic GVHD.  
o Cellular subsets identified by mass cytometry can be gated for in conventional 
flow cytometry panels. 
 
• Long-term stable MC in patients transplanted for non-malignancies is a rare 
occurrence post-HSCT. However, understanding the phenomenon may be crucial for 
early post-HSCT care as well as for pre-transplant treatment of live solid organ 
transplant recipients.  
 
o Donor grafts derived from sibling donors are more likely to result in stable 
long-term MC development than grafts from unrelated donors. 
o Long-term stable MC does not appear to be detrimental for the patients in the 
long run.  
o Recipient-derived cells appear to be present in most of the main immune cell 
subsets and are capable of responding to stimuli.  
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5.2 FUTURE STUDIES 
Apart from the study presented in Paper I on acute GVHD, the other two studies presented 
in this thesis were performed on relatively small group sizes. Hence, conclusions must be 
made with caution. Additionally, all studies in this thesis were performed in a single centre 
setting. These findings need to be confirmed in other cohorts, preferably in other centres as 
well as in new cohorts within our centre. 
 
As in most research, the studies performed in this thesis may have clarified some issues, but 
they do also raise a number of questions. I will discuss some of the things I would like to do 
in future studies.  
 
In Paper I, one of the main difficulties I faced was to include patients who later developed 
grade III-IV aGVHD. As this study was a prospective study, I included all patients and 
donors I could at time of transplantation. Unfortunately, due to logistics and chance I was 
unable to include some patients who developed grade III-IV aGVHD. Additionally, 
occurrence of grade III-IV aGVHD dropped more than expected during the inclusion 
period. Due to these difficulties, I could not analyse patients with grade II aGVHD 
separately from patients with grade III-IV aGVHD.  
 
Another issue that arose during the experimental set-up and analysis was limited access to 
patient samples. I was thus restricted in performing some of the experimental parts of the 
study.  
 
Therefore, I would like to analyse a new cohort of patients and their donors. In this new 
cohort, I would then focus primarily on the identified markers of interest (PD-1, CD127 and 
TNFa) to validate these as potential biomarkers. Additionally, by limiting the markers of 
interest I could also reduce the number of flow cytometry panels before MLR and post-
MLR. This will save sample and allow me to analyse cells at several time points during the 
MLR. This will hopefully tell us more about the activation peaks of cellular subsets, which 
in turn may tell us something on the in vitro model of aGVHD.  
 
In a new cohort of patients, I could also potentially try a different in vitro method for 
aGVHD. By using a confocal microscope and time-lapse imaging, you can track killing and 
migration of single cells over time. Target and effector cells can be labelled in different 
colours and specific killing can be monitored. I had initially hoped to use this method in 
this study but it was not possible due to high spontaneous death of cells after thawing. I 
hope this issue can be resolved so I can try out this method in the setting of aGVHD.  
 
Lastly, there are few things I have not yet analysed in context of the study. For instance, I 
also collected cells prior and after MLR for TCRgd spectra-typing. This data is currently 
being analysed. Moreover, in this study I only looked at one primary outcome, e.g. primary 
aGVHD development. I am currently further analysing the data and looking at how donor 
graft phenotype may influence other HSCT outcome variables, such as; relapse, rejection, 
infections, engraftment, cGVHD and overall survival.  
 
In Paper II, I first attempted to identify diagnostic markers for chronic GVHD through 
standard methods as tried by several before us. Though I could identify some cellular 
subsets of interest (MAIT cells) I quickly concluded I would need to utilize multi-
dimensional methods to identify novel subsets linked to cGVHD severity. Due to sample 
availability and financial limitations, I could only analyse small group sizes (around 10 
patients per grading) by mass cytometry. I then used a supplementary cohort to validate the 
mass cytometry in flow.  
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There were a few things I wanted to do in this study but could not. One of the first things 
was that I only had access to patient peripheral blood. However, to understand the 
pathophysiology of cGVHD, blood will only yield a limited amount of information. As 
cGVHD occurs primarily in the affected tissues, it would be interesting to analyse biopsies 
taken from patients suspected to suffer from cGVHD. In an ideal world, we can compare 
affected and unaffected tissue samples from the same patient and organ with their blood 
samples. I could then perhaps ascertain if there are differences in the immune phenotypes of 
infiltrating cells and whether an influx of MAIT cells from the blood towards affected 
organs could be seen. The logistics of this was unfortunately not possible for the scope of 
this thesis. Though not planned yet, perhaps it will be possible to analyse such biopsies in 
the future, though it might be difficult to obtain ethical permission especially for biopsies of 
unaffected tissue.  
 
In a new study with a new cohort of patients with cGVHD, I would like to focus on some of 
the novel cellular subsets identified in this study and elaborate on them by incorporating 
other cellular markers. This might help explain some of the mechanisms of cGVHD.  
 
Additionally, in a future study, it would be important to include patients with moderate and 
severe cGVHD who are untreated with immunosuppressive drugs for many months/years. I 
would then be able to compare patients with all cGVHD gradings to each other, which was 
not possible in this study. I could identify far fewer differences between moderate and 
severe cGVHD than between patients without cGVHD and mild cGVHD, which most 
likely was due to the immunosuppressive regimen.  
 
Moreover, as these patients may present with different organs affected by cGVHD, perhaps 
it would be better to compare them according to affected organ. For instance, the blood 
immune phenotype of patients with lung-affected cGVHD could be vastly different from 
those that do not have their lungs affected. I am currently analysing both flow and mass 
cytometry data according to the organ involvement for patients with moderate and severe 
cGVHD.  
 
Another way to compare the cGVHD patients could be by their ability to react to stimuli. I 
am currently also analysing mass cytometry data of the patients with cGVHD after PMA 
stimulation.  
 
In Paper III and IV, I focused on patients with long-term stable MC. Long-term stable MC 
is not a common occurrence, made even more complicated by our stringent inclusion 
criteria of being at least 5 years post-HSCT and transplanted for non-malignancies, 
resulting in a small sample size.  
 
We are currently discussing a follow-up clinical-oriented study on additional MC patients. 
It has been almost 5 years since I included the patients for this study and quite a few more 
patients with long-term stable MC have been identified. Moreover, as far as I am aware, all 
patients with long-term stable MC discussed in this study are still alive and doing well at 
time of writing this thesis. Hence, I would most likely be able to recruit a much larger 
group of patients in such a new study. 
 
I could then also perform chimerism analyses on more in-depth cellular subsets. This will 
help identify whether these patients retain functional recipient cells in smaller immune cell 
subsets or whether some are predominantly donor-derived. For instance, by exposing the 
patient’s lymphocytes to varying antigens I could ascertain whether the different 
hematopoietic systems react to the same extent or not. 
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Unfortunately, increasing the group size in a new study will not fix the potential selection 
bias I had in this study. Since I only included patients who survived until at least 5 years 
post-HSCT I may have a survival bias. A prospective study might alleviate some of this 
potential bias. I could then also better analyse the role of IgG3, platelets, IL-4 and ZAP-70 
deficiency in MC development.  
 
In short, we are left with perhaps more questions after the research is done than we had 
when we started. A lot of work is still needed and much more research needs to be 
performed to validate our findings. However, I feel that the research performed for this 
thesis is a good starting point for many more follow-up studies which I hope will be done in 
the near future.  
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6 POPULAR SCIENTIFIC SUMMARIES 
 
6.1 SVENSKA 
 
Vem är jag? Vad är “själv”? Var slutar jag och börjar du? 
 
Dessa frågor har sysselsatt filosofer i århundraden. Intressant är att vi alla har ett system 
inom oss som syftar till att svara på dessa frågor på daglig basis: immunsystemet. 
 
Våra kroppar attackeras dagligen av organismer som kan orsaka skada eller sjukdom. För 
att bekämpa detta är ett avancerat försvarssystem som heter immunsystemet aktivt dygnet 
runt. Immunsystemet består av ett omfattande nätverk av celler som har förmåga att 
kommunicera och utveckla lämpliga försvarsstrategier. För att immunförsvaret ska kunna 
skydda oss måste det först kunna identifiera ”själv” från ”icke-själv”. Jämför detta med en 
militär, som måste kunna identifiera vän från fiende för att förhindra vådaskjutning. 
 
Hos vissa människor fungerar inte immunsystemet lika bra som det borde. Detta kan till 
exempel bero på genetiska orsaker eller på grund av cancer i immunsystemets celler. 
Patienter som lider av ett icke-funktionellt immunförsvar kan behandlas genom att få ett 
nytt immunsystem. På liknande sätt som patienter med hjärtproblem kan få ett nytt hjärta 
från en donator, kan patienter få ett nytt immunsystem från en donator. Att donera ditt 
immunförsvar är något du gör medan du lever, eftersom endast en liten del av 
immunsystemet transplanteras. Denna del av immunsystemet kommer då att växa inuti 
patienten tills ett funktionellt immunsystem har återbildats. Denna typ av transplantation 
kallas för hematopoetisk stamcellstransplantation. 
 
Transplantation av immunsystemets celler är i de flesta fall det enda sättet att rädda dessa 
patienters liv. Denna behandling har funnits länge men det finns fortfarande ett antal 
problem som kan uppstå för patienter efter transplantationen. 
 
Till exempel, eftersom cellerna i det nya immunsystemet fortfarande är relativt få vid 
transplantation behöver de tid att växa och expandera. Under denna period av tillväxt är 
immunförsvaret inte fullt kapabelt att reagera på ett hot. Således kan en förkylning vara 
ganska problematisk för dessa patienter. Patienterna måste vara försiktiga och ta mycket 
förebyggande läkemedel. 
 
Ett av immunsystemets stora problem, som kan uppstå efter en hematopoetisk 
stamcellstransplantation, handlar om problemet med att identifiera ”själv”. Per definition är 
patientens kropp full av celler som inte är ”egna” för donatorns immunsystem. Om man inte 
gör någonting åt detta, förväntas det nya immunsystemet från donatorn känna igen 
patientcellerna som ”icke-själv” och därmed reagera. Detta kallas ”graft-versus-host” 
sjukdom. Graftet (donator immunsystemet) står motsatt host (patientens kropp) och ett krig 
bryter ut. Två av de fyra artiklar (artiklar I och II) som diskuteras i denna avhandling 
handlar om detta problem efter transplantation. I dessa artiklar har vi försökt hitta mätbara 
markörer hos patienter eller givare som kan hjälpa oss att förutsäga eller diagnostisera 
”graft-versus-host” sjukdom hos patienter. 
 
I allmänhet är målet med en hematopoetisk stamcellstransplantation att ersätta patientens 
immunförsvar helt. I sällsynta fall kvarstår en del celler från patientens eget immunsystem 
och är fortfarande närvarande tillsammans med givarens immunsystem, även många år efter 
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transplantationen. Dessa patienter har i huvudsak två immunförsvar, sitt egna och givarens. 
Detta kallas blandad chimerism. De två immunförsvaren har gjort något anmärkningsvärt, 
de har lärt sig att inte reagera på varandra och på ett sätt identifiera varandra som ”själv”. 
De två sista artiklarna (artiklar III och IV) handlar om denna blandade chimerism. Vi 
försökte ta reda på hur dessa patienter mår och hur deras immunsystem fungerar. 
 
”Graft-versus-host” sjukdom och blandad chimerism är två olika vägar som immunceller 
kan ta i en patient efter en hematopoetisk stamcellstransplantation. I det första fallet 
upplever donatorn och patienten varandra som ”icke-själv”, de är fiender och ett krig bryter 
ut. I det senare fallet har givare och patient funnit ett sätt att samexistera, tolerera varandra 
och att se varandra som ”själv” och fred råder. Vad är det i patienten som styr att det blir 
den första eller den andra vägen? Är det möjligt att förutspå i vilken riktning det kommer 
att gå, krig eller fred? Och vilken betydelse har detta för patientens välfärd? Dessa är några 
av de svåra frågor som uppkommer vid ”graft-versus-host” sjukdom och blandad 
chimerism, vilka jag har försökt att besvara i denna avhandling. 
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6.2 NEDERLANDS 
 
Wie ben ik? Wat is het “zelf”? Waar eindig ik en begin jij? 
 
Deze vragen hebben filosofen eeuwenlang geplaagd. En dat terwijl we allemaal een 
systeem in ons lichaam hebben dat dagelijks deze vragen moet beantwoorden: het 
immuunsysteem. 
 
Onze lichamen worden continu aangevallen door organismen die schade of ziekte 
veroorzaken. Om dit te bestrijden, is een ingewikkeld verdedigingssysteem 24 uur per dag 
actief, namelijk het immuunsysteem. Het immuunsysteem bestaat uit een uitgebreid 
netwerk van cellen die de mogelijkheid hebben om verdedigingsstrategieën te 
communiceren, aan te passen en te ontwikkelen. Maar wil het immuunsysteem ons goed 
beschermen, dan moet het eerst het ”zelf” van het ”niet-zelf” kunnen onderscheiden. 
Vergelijk dit met een soldaat, die een bondgenoot moet kunnen herkennen, om eigen vuur 
te voorkomen. 
 
Bij sommige mensen vertoont het immuunsysteem gebreken. Dit kan bijvoorbeeld een 
genetische oorzaak hebben of veroorzaakt worden door een vorm van kanker in het 
immuunsysteem. Patiënten die een ineffectief immuunsysteem hebben, kunnen behandeld 
worden met een transplantatie waarbij ze een nieuw immuunsysteem ontvangen van een 
donor. Het behandelingsprincipe is enigszins te vergelijken met een harttransplantatie, 
waarbij patiënten met hartproblemen een nieuw hart van een donor ontvangen. In 
tegenstelling tot een hart kun je je immuunsysteem doneren terwijl je zelf nog leeft, omdat 
slechts een klein deel van het immuunsysteem getransplanteerd wordt. Dit kleine deel van 
het immuunsysteem groeit dan in de patiënt uit tot een volledig functioneel 
immuunsysteem. Deze transplantatie wordt een hematopoietische stamceltransplantatie 
genoemd. 
 
De transplantatieprocedure is in de meeste gevallen de enige manier om het leven van 
dergelijke patiënten te redden. De procedure bestaat al lang, maar helaas zijn er nog altijd 
problemen die kunnen optreden na de transplantatie. 
 
Zo heeft het nieuwe immuunsysteem tijd nodig om te groeien. Gedurende die periode kan 
het nog niet goed reageren op een bedreiging in de vorm van een schadelijk organisme. Zo 
kan zoiets als een simpele verkoudheid bij deze patiënten voor grote problemen zorgen. 
Hierdoor moeten patiënten voorzichtig zijn en veel voorzorgsmaatregelen nemen. 
 
Eén van de belangrijkste complicaties die zich kan voordoen na een hematopoietische 
stamceltransplantatie draait om het probleem van de identificatie van het “zelf”. Het 
lichaam van de patiënt zit vol met cellen die ”niet-zelf” zijn voor de immuuncellen van de 
donor. Zonder ingrijpen zal het nieuwe immuunsysteem de cellen van de patiënt 
bestempelen als "niet-zelf" en de cellen gaan aanvallen. Dit heet graft-versus-host reactie. 
De graft (het immuunsysteem van de donor) staat tegenover de host (het lichaam van de 
patiënt) en een oorlog breekt uit. Twee van de vier artikelen (artikel I en II) die in dit 
proefschrift worden besproken gaan over dit probleem. In deze artikelen hebben we 
geprobeerd markers te vinden die we kunnen meten bij patiënten of donoren, die ons 
kunnen helpen bij het voorspellen of diagnosticeren van patiënten die aan deze complicatie 
lijden. 
 
In het algemeen is het uiteindelijke doel van een hematopoietische stamceltransplantatie dat 
het immuunsysteem van de patiënt volledig vervangen wordt. Er zijn echter zeldzame 
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gevallen, waarbij een deel van het eigen immuunsysteem van de patiënt aanwezig blijft. 
Deze patiënten hebben in wezen twee immuunsystemen, hun eigen en dat van de donor. Dit 
heet gemengd chimerisme. De twee immuunsystemen hebben iets opmerkelijks gedaan, ze 
hebben ogenschijnlijk geleerd elkaar te tolereren. De laatste twee artikelen (artikel III en 
IV) van dit proefschrift gaan over dit gemengd chimerisme. We hebben onderzocht hoe 
deze patiënten eraan toe zijn en hoe hun bijzondere mengeling van immuunsystemen 
functioneert. 
 
Graft versus-host reactie en gemengd chimerisme zijn twee verschillende paden die de 
immuuncellen binnen een patiënt kunnen bewandelen na een hematopoietische 
stamceltransplantatie. In het eerste geval herkennen de cellen van de donor de cellen van de 
patiënt als ”niet-zelf” en een oorlog breekt uit. In het tweede geval hebben de 
immuuncellen van de patiënt en de donor geleerd elkaar te tolereren, waardoor er een vorm 
van vrede ontstaat. Wat gebeurt er binnen de patiënt dat bepaalt of het ene pad of het andere 
pad bewandeld wordt? Hoe kunnen we van tevoren voorspellen welk pad bewandeld gaat 
worden? En wat betekent dit voor het welzijn van de patiënt? Dit zijn een paar van de 
vragen omtrent graft-versus-host reactie en gemengd chimerisme, die dit proefschrift heeft 
getracht te beantwoorden. 
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